WO2024015731A1 - Composés tricycliques fusionnés en tant qu'inhibiteurs de mutants kras g12v - Google Patents

Composés tricycliques fusionnés en tant qu'inhibiteurs de mutants kras g12v Download PDF

Info

Publication number
WO2024015731A1
WO2024015731A1 PCT/US2023/069872 US2023069872W WO2024015731A1 WO 2024015731 A1 WO2024015731 A1 WO 2024015731A1 US 2023069872 W US2023069872 W US 2023069872W WO 2024015731 A1 WO2024015731 A1 WO 2024015731A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
independently selected
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PCT/US2023/069872
Other languages
English (en)
Inventor
Gencheng LI
Lei Liu
Pei Gan
Chang MIN
Alexander Sokolsky
Xiaozhao Wang
Le ZHAO
Qinda YE
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corporation filed Critical Incyte Corporation
Publication of WO2024015731A1 publication Critical patent/WO2024015731A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • This disclosure provides compounds as well as their compositions and methods of use.
  • the compounds modulate KRAS activity and are useful in the treatment of various diseases including cancer.
  • Ras proteins are part of the family of small GTPases that are activated by growth factors and various extracellular stimuli.
  • the Ras family regulates intracellular signaling pathways responsible for growth, migration, survival and differentiation of cells.
  • Activation of RAS proteins at the cell membrane results in the binding of key effectors and initiation of a cascade of intracellular signaling pathways within the cell, including the RAF and PI3K kinase pathways.
  • Somatic mutations in RAS may result in uncontrolled cell growth and malignant transformation while the activation of RAS proteins is tightly regulated in normal cells (Simanshu, D. et al. Cell 170.1 (2017): 17-33).
  • the Ras family is comprised of three members: KRAS, NRAS and HRAS.
  • RAS mutant cancers account for about 25% of human cancers.
  • KRAS is the most frequently mutated isoform accounting for 85% of all RAS mutations whereas NRAS and HRAS are found mutated in 12% and 3% of all Ras mutant cancers respectively (Simanshu, D. et al. Cell 170.1 (2017): 17-33).
  • KRAS mutations are prevalent amongst the top three most deadly cancer types: pancreatic (97%), colorectal (44%), and lung (30%) (Cox, A.D. et al. Nat Rev Drug Discov (2014) 13:828-51).
  • the majority of RAS mutations occur at amino acid residue 12, 13, and 61.
  • the frequency of specific mutations varies between RAS gene isoforms and while G12 and Q61 mutations are predominant in KRAS and NRAS respectively, G12, G13 and Q61 mutations are most frequent in HRAS. Furthermore, the spectrum of mutations in a RAS isoform differs between cancer types. For example, KRAS G12D mutations predominate in pancreatic cancers (51%), followed by colorectal adenocarcinomas (45%) and lung cancers (17%) while KRAS G12 V mutations are associated with pancreatic cancers (30%), followed by colorectal adenocarcinomas (27%) and lung adenocarcinomas (23%) (Cox, A.D. et al.
  • KRAS G12C mutations predominate in non-small cell lung cancer (NSCLC) comprising 11-16% of lung adenocarcinomas, and 2-5% of pancreatic and colorectal adenocarcinomas (Cox, A.D. et al. Nat. Rev. Drug Discov. (2014) 13:828-51).
  • NSCLC non-small cell lung cancer
  • KRAS G12C mutations predominate in non-small cell lung cancer
  • NSCLC non-small cell lung cancer
  • pancreatic and colorectal adenocarcinomas Cox, A.D. et al. Nat. Rev. Drug Discov. (2014) 13:828-5.
  • Genomic studies across hundreds of cancer cell lines have demonstrated that cancer cells harboring KRAS mutations are highly dependent on KRAS function for cell growth and survival (McDonald, R. et al. Cell 170 (2017): 577- 592).
  • mutant KRAS as an oncogenic driver is further supported by extensive in vivo experimental evidence showing mutant KRAS is required for early tumour onset and maintenance in animal models (Cox, A.D. et al. Nat Rev Drug Discov (2014) 13:828-51).
  • KRAS mutations play a critical role in human cancers; development of inhibitors targeting mutant KRAS may therefore be useful in the clinical treatment of diseases that are characterized by a KRAS mutation.
  • the present disclosure provides, inter alia, a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein constituent variables are defined herein.
  • the present disclosure further provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the disclosure, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.
  • the present disclosure further provides methods of inhibiting KRAS activity, which comprises administering to an individual a compound of the disclosure, or a pharmaceutically acceptable salt thereof.
  • the present disclosure also provides uses of the compounds described herein in the manufacture of a medicament for use in therapy.
  • the present disclosure also provides the compounds described herein for use in therapy.
  • the present disclosure further provides methods of treating a disease or disorder in a patient comprising administering to the patient a therapeutically effective amount of a compound of the disclosure, or a pharmaceutically acceptable salt thereof.
  • R 2 is selected from C1.3 alkyl, halo, C1.3 haloalkyl, and -CH2CH2CN;
  • Cy 1 is selected from wherein n is 0, 1, 2, or 3;
  • R 5 is selected from H, D, methyl, Ci haloalkyl, and halo;
  • R 6 is selected from H, C1.3 alkyl, C1.3 haloalkyl, C3-6 cycloalkyl, 4-9 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, Cs-ecycloalkyl-Ci-s alkylene, 4-6 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci.3 alkylene, 5-6 membered heteroaryl-Ci.3 alkylene, halo, D, CN, OR a6 , and C(O)NR c6 R d6 ; wherein said C1.3 alkyl, C3-6 cycloalkyl, 4-9 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, Cs-e cycloalkyl-Ci-s alkylene, 4-6 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci.3 alkylene, and 5-6 membere
  • R 2 is selected from C1.3 alkyl and -CH2CH2CN;
  • Cy 1 is selected from wherein n is 1 or 2;
  • R 5 is selected from H and halo
  • R 6 is selected from pyrrolidinyl and pyrazolyl; wherein said pyrrolidinyl and pyrazolyl are each optionally substituted with 1 or 2 substituents independently selected from R 60 ; each R 10 is independently selected from halo and CN; each R 60 is independently selected from C1.3 alkyl, C(O)R b6 °, and C(O)NR c60 R d60 ; and each R b6 °, R c6 ° and R d6 ° is independently selected from H and C1.3 alkyl.
  • the compound of Formula I is a compound of Formula la:
  • R 2 is selected from C1.3 alkyl and -CH2CH2CN; Cy 1 is selected from wherein n is 1 or 2;
  • R 5 is selected from H and halo
  • R 6 is selected from 4-6 membered heterocycloalkyl and 5-6 membered heteroaryl; wherein said 4-6 membered heterocycloalkyl and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R 60 ; each R 10 is independently selected from halo and CN; each R 60 is independently selected from C1.3 alkyl, C(O)R b60 , and C(O)NR c60 R d6 °; and each R b6 °, R c6 ° and R d6 ° is independently selected from H and C1.3 alkyl.
  • R 2 is selected from C1.3 alkyl, halo, C1.3 haloalkyl, and -CH2CH2CN;
  • Cy 1 is selected from wherein n is 0, 1 , 2, or 3;
  • R 5 is selected from H, D, methyl, Ci haloalkyl, and halo;
  • R 6 is selected from H, C1.3 alkyl, C1.3 haloalkyl, C3-6 cycloalkyl, 4-9 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, Cs-ecycloalkyl-Ci-s alkylene, 4-6 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci.3 alkylene, 5-6 membered heteroaryl-Ci-3 alkylene, halo, D, CN, OR a6 , and C(O)NR c6 R d6 ; wherein said C1.3 alkyl, C3-6 cycloalkyl, 4-9 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, Cs-e cycloalkyl-Ci-s alkylene, 4-6 membered heterocycloalkyl-Ci-3 alkylene, phenyl-Ci.3 alkylene, and 5-6 membered
  • R 2 is selected from C1.3 alkyl and -CH2CH2CN;
  • Cy 1 is selected from wherein n is 1 or 2;
  • R 5 is selected from H, D, and halo
  • R 6 is selected from C1.3 alkyl, 4-8 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl; wherein said C1.3 alkyl, 4-8 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R 60 ; each R 10 is independently selected from C1.3 alkyl, halo, CN, and OR a1 °; each R 60 is independently selected from C1.3 alkyl, 4-6 membered heterocycloalkyl, 5- 6 membered heteroaryl, halo, C(O)R b60 , C(O)NR c60 R d6 °, NR c60 C(O)R b6 °, C(O)OR a6 °, NR c60 C(O)OR a6 °, and NR c60 S(O)2R b6 °; wherein said C1.3 alkyl,
  • the compound of Formula I is a compound of Formula la:
  • R 2 is selected from C1.3 alkyl and -CH2CH2CN;
  • Cy 1 is selected from
  • R 5 is selected from H and halo
  • R 6 is selected from 4-6 membered heterocycloalkyl and 5-6 membered heteroaryl; wherein said 4-6 membered heterocycloalkyl and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R 60 ; each R 10 is independently selected from halo and CN; each R 60 is independently selected from C1.3 alkyl, C(O)R b60 , and C(O)NR c60 R d6 °; and each R b6 °, R c6 ° and R d6 ° is independently selected from H and C1.3 alkyl.
  • R 2 is selected from C1.3 alkyl, C1.3 haloalkyl, and -CH2CH2CN. In an embodiment, R 2 is selected from C1.3 alkyl and -CH2CH2CN. In an embodiment, R 2 is C1.3 alkyl. In an embodiment, R 2 is methyl. In an embodiment, R 2 is -CH2CH2CN.
  • Cy 1 is selected from Cy 1 -a and Cy 1 -b. In an embodiment, Cy 1 is selected from Cy 1 -a and Cy 1 -c. In an embodiment, Cy 1 is selected from Cy 1 -b and Cy 1 -c. In an embodiment, Cy 1 is Cy 1 -a. In an embodiment, Cy 1 is Cy 1 -b. In an embodiment, Cy 1 is Cy 1 -c. In another embodiment, Cy 1 is Cy 1 -d. In yet another embodiment, In another embodiment, Cy 1 is selected from Cy 1 -a and Cy 1 -d.
  • n is 0, 1 , or 2. In an embodiment, n is 1 or 2. In an embodiment, n is 0. In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3.
  • R 5 is selected from H, D, methyl, and halo. In an embodiment, R 5 is selected from H, D, and, halo. In an embodiment, R 5 is selected from H and halo. In an embodiment, R 5 is H. In an embodiment, R 5 is halo. In an embodiment, R 5 is selected from chloro and fluoro. In an embodiment, R 5 is chloro. In an embodiment, R 5 is fluoro.
  • R 6 is selected from C1.3 alkyl, C1.3 haloalkyl, C3-6 cycloalkyl, 4-9 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, halo, CN, OR a6 , and C(O)NR c6 R d6 ; wherein said C1.3 alkyl, C3-6 cycloalkyl, 4-9 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, Cs-e cycloalkyl-Ci .3 alkylene, 4-6 membered heterocycloalkyl-Ci.3 alkylene, phenyl-Ci.3 alkylene, and 5-6 membered heteroaryl-Ci.3 alkylene are each optionally substituted with 1 or 2 substituents independently selected from R 60 .
  • R 6 is selected from C1.3 alkyl, 4-8 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl; wherein said C1.3 alkyl, 4-8 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R 60 .
  • R 6 is selected from 4-6 membered heterocycloalkyl and 5-6 membered heteroaryl; wherein said 4-6 membered heterocycloalkyl and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R 60 .
  • R 6 is 4-6 membered heterocycloalkyl; wherein said 4-6 membered heterocycloalkyl is optionally substituted with 1 or 2 substituents independently selected from R 60 .
  • R 6 is 5-6 membered heterocycloalkyl; wherein said 5-6 membered heterocycloalkyl is optionally substituted with 1 or 2 substituents independently selected from R 60 .
  • R 6 is 5 membered heterocycloalkyl; wherein said 5 membered heterocycloalkyl is optionally substituted with 1 or 2 substituents independently selected from R 60 .
  • R 6 is pyrrolidinyl; wherein said pyrrolidinyl is optionally substituted with 1 or 2 substituents independently selected from R 60 .
  • R 6 is 5-6 membered heteroaryl; wherein said 5-6 membered heteroaryl is optionally substituted with 1 or 2 substituents independently selected from R 60 .
  • R 6 is 5 membered heteroaryl; wherein said 5 membered heteroaryl is optionally substituted with 1 or 2 substituents independently selected from R 60 .
  • R 6 is pyrazolyl; wherein said pyrazolyl is optionally substituted with 1 or 2 substituents independently selected from R 60 .
  • each R 10 is independently selected from C1.3 alkyl, C1.3 haloalkyl, halo, D, CN, and OR a1 °. In an embodiment, each R 10 is independently selected from C1.3 alkyl, halo, CN, and OR a1 °. In an embodiment, each R 10 is independently selected from halo and CN. In an embodiment, each R 10 is independently selected from halo. In an embodiment, each R 10 is independently selected from chloro and fluoro. In an embodiment, each R 10 is chloro. In an embodiment, each R 10 is CN.
  • each R 60 is independently selected from C1.3 alkyl, C1.3 haloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, halo, C(O)R b60 , C(O)NR c60 R d6 °, NR c60 C(O)R b6 °, C(O)OR a6 °, NR c60 C(O)OR a6 °, NR c60 R d6 °, NR c60 S(O) 2 R b6 °, and S(O) 2 R b6 °; wherein said C1.3 alkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R 61 .
  • each R 60 is independently selected from C1.3 alkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, halo, C(O)R b6 °, C(O)NR c60 R d6 °, NR c60 C(O)R b6 °, C(O)OR a6 °, NR c60 C(O)OR a6 °, and NR c60 S(O) 2 R b6 °; wherein said C1.3 alkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R 61 .
  • each R 60 is independently selected from C1.3 alkyl, C(O)R b6 °, and C(O)NR c60 R d6 °. In another embodiment, each R 60 is independently selected from methyl, C(O)R b6 ° and C(O)NR c60 R d6 °. In an embodiment, each R 60 is independently selected from C(O)R b6 ° and C(O)NR c60 R d6 °. In another embodiment, R 60 is C(O)R b6 °. In yet another embodiment, R 60 is C(O)NR c60 R d6 °. In still another embodiment, R 60 is C1.3 alkyl. In another embodiment, R 60 is methyl.
  • each R 61 is independently selected from C1.3 alkyl, C1.3 haloalkyl, and halo.
  • each R a6 °, R b6 °, R c6 ° and R d6 ° is independently selected from H, C1.3 alkyl, C1.3 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl; wherein said C1.3 alkyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R 61 ; or any R c6 ° and R d6 ° attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, or 6-membered heterocycloalkyl group optionally substituted with 1 or 2 substituents independently selected from R 61 .
  • each R b6 °, R c6 ° and R d6 ° is independently selected from H and C1.3 alkyl. In an embodiment, each R b6 °, R c6 ° and R d6 ° is independently selected from C1.3 alkyl. In an embodiment, each R b6 °, R c6 ° and R d6 ° is methyl. In an embodiment, R b6 ° is C1.3 alkyl. In another embodiment, R c6 ° and R d6 ° are each independently C1.3 alkyl.
  • the compound of Formula I is selected from:
  • the compound of Formula I is selected from:
  • the compound of Formula I is selected from:
  • the compound of Formula I is selected from:
  • the compound of Formula I is selected from:
  • the compound of Formula I is a pharmaceutically acceptable salt.
  • a pharmaceutical composition comprising a compound of Formula I, or any of the embodiments thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • Ci-e alkyl is specifically intended to individually disclose (without limitation) methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl and Ce alkyl.
  • n-membered typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n.
  • piperidinyl is an example of a 6-membered heterocycloalkyl ring
  • pyrazolyl is an example of a 5-membered heteroaryl ring
  • pyridyl is an example of a 6-membered heteroaryl ring
  • 1 ,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.
  • each linking substituent include both the forward and backward forms of the linking substituent.
  • -NR(CR'R") n - includes both -NR(CR'R") n - and -(CR'R") n NR- and is intended to disclose each of the forms individually.
  • the Markush variables listed for that group are understood to be linking groups. For example, if the structure requires a linking group and the Markush group definition for that variable lists “alkyl” or “aryl” then it is understood that the “alkyl” or “aryl” represents a linking alkylene group or arylene group, respectively.
  • substituted means that an atom or group of atoms formally replaces hydrogen as a “substituent” attached to another group.
  • the hydrogen atom is formally removed and replaced by a substituent.
  • a single divalent substituent e.g., oxo
  • optionally substituted means unsubstituted or substituted.
  • substituted refers to any level of substitution, e.g., mono-, di-, tri-, tetra- or penta-substitution, where such substitution is permitted.
  • the substituents are independently selected, and substitution may be at any chemically accessible position.
  • substitution at a given atom is limited by valency. It is to be understood that substitution at a given atom results in a chemically stable molecule.
  • optionally substituted means unsubstituted or substituted.
  • substituted means that a hydrogen atom is removed and replaced by a substituent.
  • a single divalent substituent, e.g., oxo, can replace two hydrogen atoms.
  • C n -m indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons present in a chemical moiety. The term is intended to include each and every member in the indicated range.
  • C n -m includes each member in the series C n , C n +i , ... C m -i, and C m .
  • Examples include C1.4 (which includes Ci , C2, C3, and C4) , C1.6 (which includes Ci , C2, C3, C4, C5, and Ce) and the like.
  • alkyl employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chained or branched.
  • C n -m alkyl refers to an alkyl group having n to m carbon atoms.
  • An alkyl group formally corresponds to an alkane with one C-H bond replaced by the point of attachment of the alkyl group to the remainder of the compound.
  • the alkyl group contains from 1 to 6 carbon atoms, from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or 1 to 2 carbon atoms.
  • alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, terf-butyl, isobutyl, sec-butyl; higher homologs such as 2-methyl-1 -butyl, n-pentyl, 3-pentyl, n-hexyl, 1 ,2,2-trimethylpropyl and the like.
  • alkylene employed alone or in combination with other terms, refers to a divalent alkyl linking group.
  • An alkylene group formally corresponds to an alkane with two C-H bond replaced by points of attachment of the alkylene group to the remainder of the compound.
  • C n -m alkylene refers to an alkylene group having n to m carbon atoms.
  • alkylene groups include, but are not limited to, methylene, ethan-1 ,2- diyl, ethan-1 , 1-diyl, propan-1 , 3-diyl, propan-1 , 2-diyl, propan-1 , 1-diyl, butan-1 ,4-diyl, butan- 1 ,3-diyl, butan-1 , 2-diyl, 2-methyl-propan-1 , 3-diyl and the like.
  • halo refers to fluoro, chloro, bromo and iodo.
  • halo refers to a halogen atom selected from F, Cl, or Br.
  • halo groups are F.
  • haloalkyl refers to an alkyl group in which one or more of the hydrogen atoms has been replaced by a halogen atom.
  • C n -m haloalkyl refers to a C n -m alkyl group having n to m carbon atoms and from at least one up to ⁇ 2(n to m)+1 ⁇ halogen atoms, which may either be the same or different.
  • the halogen atoms are fluoro atoms.
  • the haloalkyl group has 1 to 6 or 1 to 4 carbon atoms.
  • Example haloalkyl groups include CF3, C2F5, CHF2, CH2F, CCI3, CHCI2, C2CI5 and the like.
  • the haloalkyl group is a fluoroalkyl group.
  • aromatic refers to a carbocycle or heterocycle having one or more polyunsaturated rings having aromatic character (/.e., having (4n + 2) delocalized (pi) electrons where n is an integer).
  • aryl refers to an aromatic hydrocarbon group, which may be monocyclic or polycyclic (e.g., having 2 fused rings).
  • C n -m aryl refers to an aryl group having from n to m ring carbon atoms.
  • Aryl groups include, e.g., phenyl, naphthyl, and the like. In some embodiments, aryl groups have from 6 to about 10 carbon atoms. In some embodiments, aryl groups have 6 carbon atoms. In some embodiments, aryl groups have 10 carbon atoms. In some embodiments, the aryl group is phenyl. In some embodiments, the aryl group is naphthyl.
  • heteroaryl or “heteroaromatic,” employed alone or in combination with other terms, refers to a monocyclic or polycyclic aromatic heterocycle having at least one heteroatom ring member selected from sulfur, oxygen and nitrogen.
  • the heteroaryl ring has 1 , 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen.
  • any ring-forming N in a heteroaryl moiety can be an N-oxide.
  • the heteroaryl has 5-14 ring atoms including carbon atoms and 1 , 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen.
  • the heteroaryl has 5-10 ring atoms including carbon atoms and 1 , 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl has 5-6 ring atoms and 1 or 2 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl is a five-membered or six-membered heteroaryl ring. In other embodiments, the heteroaryl is an eight-membered, nine-membered or ten-membered fused bicyclic heteroaryl ring.
  • Example heteroaryl groups include, but are not limited to, pyridinyl (pyridyl), pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, azolyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, furanyl, thiophenyl, quinolinyl, isoquinolinyl, naphthyridinyl (including 1 ,2-, 1 ,3-, 1 ,4-, 1 ,5-, 1 ,6-, 1 ,7-, 1 ,8-, 2,3- and 2,6-naphthyridine), indolyl, isoindolyl, benzothiophenyl, benzofuranyl, benzisoxazolyl, imidazo[1 ,2-b]thiazolyl, purinyl, and the like.
  • the heteroaryl group include,
  • a five-membered heteroaryl ring is a heteroaryl group having five ring atoms wherein one or more (e.g., 1 , 2 or 3) ring atoms are independently selected from N, O and S.
  • Exemplary five-membered ring heteroaryls include thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1 ,2,3-triazolyl, tetrazolyl, 1 ,2,3- thiadiazolyl, 1 ,2,3-oxadiazolyl, 1 ,2,4-triazolyl, 1 ,2,4-thiadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,3,4- triazolyl, 1 ,3,4-thiadiazolyl and 1 ,3,4-oxadiazolyl.
  • a six-membered heteroaryl ring is a heteroaryl group having six ring atoms wherein one or more (e.g., 1 , 2 or 3) ring atoms are independently selected from N, O and S.
  • Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl, isoindolyl, and pyridazinyl.
  • cycloalkyl refers to a non-aromatic hydrocarbon ring system (monocyclic, bicyclic or polycyclic), including cyclized alkyl and alkenyl groups.
  • C n -m cycloalkyl refers to a cycloalkyl that has n to m ring member carbon atoms.
  • Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) groups and spirocycles. Cycloalkyl groups can have 3, 4, 5, 6 or 7 ringforming carbons (C3-7).
  • the cycloalkyl group has 3 to 6 ring members, 3 to 5 ring members, or 3 to 4 ring members. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is a C3-6 monocyclic cycloalkyl group. Ring-forming carbon atoms of a cycloalkyl group can be optionally oxidized to form an oxo or sulfido group. Cycloalkyl groups also include cycloalkylidenes.
  • cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (/.e., having a bond in common with) to the cycloalkyl ring, e.g., benzo or thienyl derivatives of cyclopentane, cyclohexane and the like.
  • a cycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring.
  • cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, bicyclo[1.1.1]pentanyl, bicyclo[2.1.1]hexanyl, and the like.
  • the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • heterocycloalkyl refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene groups as part of the ring structure, which has at least one heteroatom ring member independently selected from nitrogen, sulfur, oxygen and phosphorus, and which has 4-10 ring members, 4-7 ring members, or 4-6 ring members. Included within the term “heterocycloalkyl” are monocyclic 4-, 5-, 6- and 7-membered heterocycloalkyl groups. Heterocycloalkyl groups can include mono- or bicyclic (e.g., having two fused or bridged rings) or spirocyclic ring systems.
  • the heterocycloalkyl group is a monocyclic group having 1 , 2 or 3 heteroatoms independently selected from nitrogen, sulfur and oxygen. Ring-forming carbon atoms and heteroatoms of a heterocycloalkyl group can be optionally oxidized to form an oxo or sulfido group or other oxidized linkage (e.g., C(O), S(O), C(S) or S(O) 2 , /V-oxide etc.) or a nitrogen atom can be quaternized.
  • the heterocycloalkyl group can be attached through a ring-forming carbon atom or a ringforming heteroatom. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds.
  • the heterocycloalkyl group contains 0 to 2 double bonds. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (/.e., having a bond in common with) to the heterocycloalkyl ring, e.g., benzo or thienyl derivatives of piperidine, morpholine, azepine, etc.
  • a heterocycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring.
  • heterocycloalkyl groups examples include 2,5-diazobicyclo[2.2.1]heptanyl; pyrrolidinyl; hexahydropyrrolo[3,4-b]pyrrol-1(2/7)-yl; 1,6- dihydropyridinyl; morpholinyl; azetidinyl; piperazinyl; and 4,7-diazaspiro[2.5]octan-7-yl.
  • the definitions or embodiments refer to specific rings (e.g., an azetidine ring, a pyridine ring, etc.). Unless otherwise indicated, these rings can be attached to any ring member provided that the valency of the atom is not exceeded. For example, an azetidine ring may be attached at any position of the ring, whereas an azetidin-3-yl ring is attached at the 3-position.
  • the compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated.
  • One method includes fractional recrystallization using a chiral resolving acid which is an optically active, salt-forming organic acid.
  • Suitable resolving agents for fractional recrystallization methods are, e.g., optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as - camphorsulfonic acid.
  • resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of a-methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N- methylephedrine, cyclohexylethylamine, 1 ,2-diaminocyclohexane and the like.
  • Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine).
  • an optically active resolving agent e.g., dinitrobenzoylphenylglycine
  • Suitable elution solvent composition can be determined by one skilled in the art.
  • the compounds of the invention have the (Reconfiguration. In other embodiments, the compounds have the (S)-configuration.
  • each of the chiral centers in the compound may be independently (R) or (S), unless otherwise indicated.
  • the stereochemistry of the chiral center can be (R) or (S).
  • the stereochemistry of the chiral centers can each be independently (R) or (S) so the configuration of the chiral centers can be (/?) and (/?), (/?) and (S); (S) and (/?), or (S) and (S).
  • each of the three chiral centers can each be independently (/?) or (S) so the configuration of the chiral centers can be (/?), (/?) and (/?); (/?), (/?) and (S); (/?), (S) and (/?); (/?), (S) and (S); (S), (/?) and (/?); (S), (/?) and (S); (S), (S), (S) and (/?); or (S), (S) and (S).
  • Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton.
  • Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge.
  • Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, e.g., H- and 3/7-imidazole, 1/7-, 2/7- and 4/7- 1 ,2,4-triazole, 1/7- and 2/7- isoindole and 1/7- and 2/7-pyrazole.
  • Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
  • Atropisomers can be stable at ambient temperature and separable, e.g., by chromatography.
  • compounds of the invention can exist in the form of atropisomers that are interchangeable by rotation around the bond connecting Cy 1 (or any of the embodiments thereof) to the remainder of the molecule.
  • Reference to the compounds described herein or any of the embodiments is understood to include all such atropisomeric forms of the compounds.
  • one atropisomer may be more potent as an inhibitor of KRAS (including G12C, G12D or G12V mutated forms of KRAS) than another atropisomer.
  • Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include tritium and deuterium.
  • One or more constituent atoms of the compounds of the invention can be replaced or substituted with isotopes of the atoms in natural or non-natural abundance.
  • the compound includes at least one deuterium atom.
  • one or more hydrogen atoms in a compound of the present disclosure can be replaced or substituted by deuterium.
  • the compound includes two or more deuterium atoms.
  • the compound includes 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 deuterium atoms.
  • Synthetic methods for including isotopes into organic compounds are known in the art (Deuterium Labeling in Organic Chemistry by Alan F. Thomas (New York, N.Y., Appleton-Century-Crofts, 1971 ; The Renaissance of H/D Exchange by Jens Atzrodt, Volker Derdau, Thorsten Fey and Jochen Zimmermann, Angew. Chem. Int. Ed. 2007, 7744-7765; The Organic Chemistry of Isotopic Labelling by James R. Hanson, Royal Society of Chemistry, 2011). Isotopically labeled compounds can used in various studies such as NMR spectroscopy, metabolism experiments, and/or assays.
  • compound as used herein is meant to include all stereoisomers, geometric isomers, tautomers and isotopes of the structures depicted.
  • the term is also meant to refer to compounds of the inventions, regardless of how they are prepared, e.g., synthetically, through biological process (e.g., metabolism or enzyme conversion), or a combination thereof.
  • All compounds, and pharmaceutically acceptable salts thereof can be found together with other substances such as water and solvents (e.g., hydrates and solvates) or can be isolated.
  • solvents e.g., hydrates and solvates
  • the compounds described herein and salts thereof may occur in various forms and may, e.g., take the form of solvates, including hydrates.
  • the compounds may be in any solid state form, such as a polymorph or solvate, so unless clearly indicated otherwise, reference in the specification to compounds and salts thereof should be understood as encompassing any solid state form of the compound.
  • the compounds provided herein, or salts thereof are substantially isolated. “Substantially isolated” means that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, e.g., a composition enriched in the compounds of the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the invention, or salt thereof.
  • phrases “pharmaceutically acceptable” refers to those compounds, materials, compositions and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • ambient temperature and “room temperature,” are understood in the art, and refer generally to a temperature, e.g., a reaction temperature, that is about the temperature of the room in which the reaction is carried out, e.g., a temperature from about 20 °C to about 30 °C.
  • a temperature e.g., a reaction temperature
  • the present disclosure also includes pharmaceutically acceptable salts of the compounds described herein, including any of the embodiments thereof.
  • pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form.
  • Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts of the present invention include the non-toxic salts of the parent compound formed, e.g., from non-toxic inorganic or organic acids.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol or butanol) or acetonitrile (MeCN) are preferred.
  • non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol or butanol) or acetonitrile (MeCN) are preferred.
  • suitable salts are found in Remington's Pharmaceutical Sciences, 17 th Ed., (Mack Publishing Company, Easton, 1985), p. 1418, Berge et al., J. Pharm. Sci., 1977, 66(1), 1-19 and in Stahl et al., Handbook of Pharmaceutical
  • the reactions for preparing compounds of the invention can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis.
  • suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature.
  • a given reaction can be carried out in one solvent or a mixture of more than one solvent.
  • suitable solvents for a particular reaction step can be selected by the skilled artisan.
  • Preparation of compounds of the invention can involve the protection and deprotection of various chemical groups.
  • the need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art.
  • the chemistry of protecting groups is described, e.g., in Kocienski, Protecting Groups, (Thieme, 2007); Robertson, Protecting Group Chemistry, (Oxford University Press, 2000); Smith et al., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 6 th Ed. (Wiley, 2007); Peturssion et al., “Protecting Groups in Carbohydrate Chemistry,” J. Chem.
  • Reactions can be monitored according to any suitable method known in the art.
  • product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry or by chromatographic methods such as high-performance liquid chromatography (HPLC), liquid chromatography-mass spectroscopy (LCMS), or thin layer chromatography (TLC).
  • spectroscopic means such as nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry or by chromatographic methods such as high-performance liquid chromatography (HPLC), liquid chromatography-mass spectroscopy (LCMS), or thin layer chromatography (TLC).
  • HPLC high-performance liquid chromatography
  • LCMS liquid chromatography-mass spectroscopy
  • HPLC high performance liquid chromatography
  • Compounds of formula 1-18 can be prepared via the synthetic route outlined in Scheme 1. Iodination of starting material 1-1 with /V-iodo-succinimide (NIS), affords intermediate 1-2.
  • Compound 1-3 can be prepared by treating 1-2 with reagents such as triphosgene. Intermediate 1-3 can then react with ethyl nitroacetate to deliver the nitro compound 1-4, which can be treated with an appropriate reagent (e.g. POC ) to afford compound 1-5. Consecutive SNAr reactions of intermediate 1-5 with amine 1-6 and sodium thiomethoxide can be carried out to generate compound 1-7.
  • the methyl thioether group in 1-14 can be oxidized and replaced by the deprotonated form of the alcohol 1-15 to afford compound 1-16.
  • the bromo group of 1-16 can be converted to Cy 1 via transition metal mediated coupling or other suitable method to obtain 1-17.
  • 1-17 can optionally undergo SnAr or other appropriate transformations to install group R 5 , which after protecting group (PG) removal provides compounds of the formula 1-18.
  • Compound 2-11 can be prepared by reacting 2-8 with a suitable reagent, such as ethyl malonate, then treating the resulting intermediate 2-10 with POCI3.
  • a suitable reagent such as ethyl malonate
  • An SNAr reaction of intermediate 2-11 with amine 2-12 affords 2-13.
  • Ester hydrolysis to afford 2-14 can be followed by iodination with /V-iodo-succinimide to generate intermediate 2-15.
  • Sonogashira coupling reaction with the appropriate alkyne affords 2-17, which after cyclization provides compound 2-18.
  • Ether functionality 2-19 can be installed by a suitable transformation, such as palladium catalyzed carbon-oxygen coupling to afford intermediate 2-20.
  • Protecting group removal provides compounds of the formula 2-21.
  • the general schemes described above and specific methods described herein for preparing particular compounds can be modified.
  • the products or intermediates can be modified to introduce particular functional groups.
  • the substituents can be modified at any step of the overall synthesis by methods know to one skilled in the art, e.g., as described by Larock, Comprehensive Organic Transformations: A Guide to Functional Group Preparations (Wiley, 1999); and Katritzky et al. (Ed.), Comprehensive Organic Functional Group Transformations (Pergamon Press 1996).
  • Compounds of the present disclosure are useful for therapy as described in further detail below.
  • the present disclosure provides compounds of Formula (I), for use as a medicament, or for use in medicine.
  • the present disclosure provides compounds of Formula (I), for use as a medicament, or for use in treating disease, as described in further detail below.
  • the present disclosure also provides the use of compounds of Formula (I), or any of the embodiments thereof, as a medicament, or for treating disease, as described in further detail below.
  • the present disclosure also provides the use of compounds of Formula (I), or any of the embodiments thereof, in the manufacture of medicament for treating disease, as described in further detail below.
  • KRAS inhibitors are KRAS inhibitors and, thus, are useful in treating diseases and disorders associated with activity of KRAS.
  • any of the compounds of Formula (I), including any of the embodiments thereof, may be used.
  • compounds of the invention are KRAS inhibitors having activity against one or more mutant forms of KRAS, and, thus, are useful in treating diseases and disorders associated with the presence or activity of mutant forms of KRAS, such as G12C, G12D, and/or the G12V mutant forms of KRAS.
  • the Ras family is comprised of three members: KRAS, NRAS and HRAS.
  • RAS mutant cancers account for about 25% of human cancers.
  • KRAS is the most frequently mutated isoform in human cancers: 85% of all RAS mutations are in KRAS, 12% in NRAS, and 3% in HRAS (Simanshu, D. et al. Cell 170.1 (2017):17-33).
  • KRAS mutations are prevalent amongst the top three most deadly cancer types: pancreatic (97%), colorectal (44%), and lung (30%) (Cox, A.D. et al. Nat Rev Drug Discov (2014) 13:828-51).
  • RAS mutations occur at amino acid residues/codons 12, 13, and 61; Codon 12 mutations are most frequent in KRAS.
  • the frequency of specific mutations varied between RAS genes and G12D mutations are most predominant in KRAS whereas Q61R and G12R mutations are most frequent in NRAS and HRAS.
  • the spectrum of mutations in a RAS isoform differs between cancer types. For example, KRAS G12D mutations predominate in pancreatic cancers (51%), followed by colorectal adenocarcinomas (45%) and lung cancers (17%) (Cox, A.D. et al. Nat Rev Drug Discov (2014) 13:828-51).
  • KRAS G12C mutations predominate in non-small cell lung cancer (NSCLC) comprising 11-16% of lung adenocarcinomas (nearly half of mutant KRAS is G12C), as well as 2-5% of pancreatic and colorectal adenocarcinomas, respectively (Cox, A.D. et al. Nat. Rev. Drug Discov. (2014) 13:828-51).
  • NSCLC non-small cell lung cancer
  • G12C non-small cell lung cancer
  • KRAS mutations play a critical role in human cancers. Development of inhibitors targeting KRAS, including mutant KRAS, will therefore be useful in the clinical treatment of diseases that are characterized by involvement of KRAS, including dieases characterized by the involvement or presence of a KRAS mutation.
  • the cancers can include adrenal cancer, acinic cell carcinoma, acoustic neuroma, acral lentiginous melanoma, acrospiroma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenomatoid odontogenic tumor, adenosquamous carcinoma, adipose tissue neoplasm, adrenocortical carcinoma, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastic
  • the cancer can be adenocarcinoma, adult T-cell leukemia/lymphoma, bladder cancer, blastoma, bone cancer, breast cancer, brain cancer, carcinoma, myeloid sarcoma, cervical cancer, colorectal cancer, esophageal cancer, gastrointestinal cancer, glioblastoma multiforme, glioma, gallbladder cancer, gastric cancer, head and neck cancer, Hodgkin's lymphoma, nonHodgkin's lymphoma, intestinal cancer, kidney cancer, laryngeal cancer, leukemia, lung cancer, lymphoma, liver cancer, small cell lung cancer, non-small cell lung cancer, mesothelioma, multiple myeloma, ocular cancer, optic nerve tumor, oral cancer, ovarian cancer, pituitary tumor, primary central nervous system lymphoma, prostate cancer, pancreatic cancer, pharyngeal cancer, renal cell carcinoma, rectal cancer, sarcoma, skin
  • carcinomas e.g., pancreatic, colorectal, lung, bladder, gastric, esophageal, breast, head and neck, cervical skin, thyroid
  • hematopoietic malignancies e.g., myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), chronic and juvenile myelomonocytic leukemia (CMML and JMML), acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and multiple myeloma (MM)
  • other neoplasms e.g., glioblastoma and sarcomas.
  • KRAS mutations were found in acquired resistance to anti-EGFR therapy (Knickelbein, K.et al. Genes & Cancer, (2015): 4-12). KRAS mutations were found in immunological and inflammatory disorders (Fernandez-Medarde, A. et al. Genes & Cancer, (2011): 344-358) such as Ras-associated lymphoproliferative disorder (RALD) or juvenile myelomonocytic leukemia (JMML) caused by somatic mutations of KRAS or NRAS. In an embodiment, the somatic mutation of KRAS is G12V.
  • Compounds of the present disclosure can inhibit the activity of the KRAS protein.
  • compounds of the present disclosure can be used to inhibit activity of KRAS in a cell or in an individual or patient in need of inhibition of the enzyme by administering an inhibiting amount of one or more compounds of the present disclosure to the cell, individual, or patient.
  • the compounds of the present disclosure are useful in the treatment of various diseases associated with abnormal expression or activity of KRAS.
  • Compounds which inhibit KRAS will be useful in providing a means of preventing the growth or inducing apoptosis in tumors, or by inhibiting angiogenesis. It is therefore anticipated that compounds of the present disclosure will prove useful in treating or preventing proliferative disorders such as cancers.
  • tumors with activating mutants of receptor tyrosine kinases or upregulation of receptor tyrosine kinases may be particularly sensitive to the inhibitors.
  • a method of inhibiting KRAS activity comprising contacting a compound of the instant disclosure with KRAS.
  • the contacting comprises administering the compound to a patient.
  • a method of inhibiting a KRAS protein harboring a G12C mutation comprising contacting a compound of Formula (I), or any of the embodiments thereof, with KRAS harboring a G12C mutation.
  • a method of inhibiting a KRAS protein harboring a G12D mutation comprising contacting a compound of Formula (I), or any of the embodiments thereof, with KRAS harboring a G12D mutation.
  • a method of inhibiting a KRAS protein harboring a G12V mutation comprising contacting a compound of Formula (I), or any of the embodiments thereof, with KRAS harboring a G12V mutation.
  • a method of treating a disease or disorder associated with inhibition of KRAS interaction comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I), or any of the embodiments thereof,, or pharmaceutically acceptable salt thereof.
  • a method of treating a disease or disorder associated with inhibiting a KRAS protein harboring a G12D mutation comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I), or any of the embodiments thereof,, or pharmaceutically acceptable salt thereof.
  • provided herein is also a method of treating cancer in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or any of the embodiments thereof, wherein the cancer is characterized by an interaction with a KRAS protein harboring a G12D mutation.
  • a method of treating a disease or disorder associated with inhibiting a KRAS protein harboring a G12V mutation comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I), or any of the embodiments thereof,, or pharmaceutically acceptable salt thereof.
  • provided herein is also a method of treating cancer in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or any of the embodiments thereof, wherein the cancer is characterized by an interaction with a KRAS protein harboring a G12V mutation.
  • provided herein is a method for treating a cancer in a patient, said method comprising administering to the patient a therapeutically effective amount of any one of the compounds disclosed herein, or pharmaceutically acceptable salt thereof.
  • a method for treating a disease or disorder associated with inhibition of KRAS interaction or a mutant thereof, in a patient in need thereof comprising the step of administering to the patient a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound disclosed herein or a pharmaceutically acceptable salt thereof, in combination with another therapy or therapeutic agent as described herein.
  • a method of treating a cancer in a patient comprising: identifying that a patient is in need of treatment of a cancer and that abnormally proliferating cells of the cancer comprise KRAS having a G12V mutation; and administering to a patient a therapeutically effective amount of the compound provided herein, or a pharmaceutically acceptable salt thereof.
  • a method of treating a cancer in a patient comprising: identifying that a patient is in need of treatment of a cancer and that abnormally proliferating cells of the cancer comprise KRAS having a G12D mutation; and administering to a patient a therapeutically effective amount of the compound provided herein, or a pharmaceutically acceptable salt thereof.
  • the cancer is selected from hematological cancers, sarcomas, lung cancers, gastrointestinal cancers, genitourinary tract cancers, liver cancers, bone cancers, nervous system cancers, gynecological cancers, and skin cancers.
  • the lung cancer is selected from non-small cell lung cancer (NSCLC), small cell lung cancer, bronchogenic carcinoma, squamous cell bronchogenic carcinoma, undifferentiated small cell bronchogenic carcinoma, undifferentiated large cell bronchogenic carcinoma, adenocarcinoma, bronchogenic carcinoma, alveolar carcinoma, bronchiolar carcinoma, bronchial adenoma, chondromatous hamartoma, mesothelioma, pavicellular and non-pavicellular carcinoma, bronchial adenoma, and pleuropulmonary blastoma.
  • NSCLC non-small cell lung cancer
  • small cell lung cancer bronchogenic carcinoma, squamous cell bronchogenic carcinoma, undifferentiated small cell bronchogenic carcinoma, undifferentiated large cell bronchogenic carcinoma, adenocarcinoma, bronchogenic carcinoma, alveolar carcinoma, bronchiolar carcinoma, bronchial adenoma, chondromatous hamartoma, mesot
  • the lung cancer is non-small cell lung cancer (NSCLC). In still another embodiment, the lung cancer is adenocarcinoma.
  • the gastrointestinal cancer is selected from esophagus squamous cell carcinoma, esophagus adenocarcinoma, esophagus leiomyosarcoma, esophagus lymphoma, stomach carcinoma, stomach lymphoma, stomach leiomyosarcoma, exocrine pancreatic carcinoma, pancreatic ductal adenocarcinoma, pancreatic insulinoma, pancreatic glucagonoma, pancreatic gastrinoma, pancreatic carcinoid tumors, pancreatic vipoma, small bowel adenocarcinoma, small bowel lymphoma, small bowel carcinoid tumors, Kaposi's sarcoma, small bowel leiomyoma, small bowel hemangioma, small bowel lipoma, small bowel neurofibroma, small bowel fibroma, large bowel adenocarcinoma, large bowel tubular a
  • the gastrointestinal cancer is colorectal cancer.
  • the cancer is a carcinoma.
  • the carcinoma is selected from pancreatic carcinoma, colorectal carcinoma, lung carcinoma, bladder carcinoma, gastric carcinoma, esophageal carcinoma, breast carcinoma, head and neck carcinoma, cervical skin carcinoma, and thyroid carcinoma.
  • the cancer is a hematopoietic malignancy.
  • the hematopoietic malignancy is selected from multiple myeloma, acute myelogenous leukemia, and myeloproliferative neoplasms.
  • the cancer is a neoplasm.
  • the neoplasm is glioblastoma or sarcomas.
  • the disclosure provides a method for treating a KRAS- mediated disorder in a patient in need thereof, comprising the step of administering to said patient a compound according to the invention, or a pharmaceutically acceptable composition thereof.
  • diseases and indications that are treatable using the compounds of the present disclosure include, but are not limited to hematological cancers, sarcomas, lung cancers, gastrointestinal cancers, genitourinary tract cancers, liver cancers, bone cancers, nervous system cancers, gynecological cancers, and skin cancers.
  • Exemplary hematological cancers include lymphomas and leukemias such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, Non-Hodgkin lymphoma (including relapsed or refractory NHL and recurrent follicular), Hodgkin lymphoma, myeloproliferative diseases (e.g., primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocytosis (ET), 8p11 myeloproliferative syndrome, myelodysplasia syndrome (MDS), T-cell acute lymphoblastic lymphoma (T-ALL), multiple myeloma, cutaneous T-cell lymphoma, adult
  • Exemplary sarcomas include chondrosarcoma, Ewing’s sarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, rhabdosarcoma, fibroma, lipoma, harmatoma, lymphosarcoma, leiomyosarcoma, and teratoma.
  • Exemplary lung cancers include non-small cell lung cancer (NSCLC), small cell lung cancer, bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, chondromatous hamartoma, mesothelioma, pavicellular and non-pavicellular carcinoma, bronchial adenoma and pleuropulmonary blastoma.
  • NSCLC non-small cell lung cancer
  • small cell lung cancer bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, chondromatous hamartoma, mesothelioma, pavicellular and non-pavicellular carcinoma, bronchial adenoma and pleuropulmonary blastoma.
  • Exemplary gastrointestinal cancers include cancers of the esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (exocrine pancreatic carcinoma, ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colorectal cancer, gall bladder cancer and anal cancer.
  • esophagus squa
  • Exemplary genitourinary tract cancers include cancers of the kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], renal cell carcinoma), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma) and urothelial carcinoma.
  • kidney adenocarcinoma, Wilm's tumor [nephroblastoma], renal cell carcinoma
  • bladder and urethra squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma
  • prostate adenocarcinoma, sarcoma
  • testis se
  • liver cancers include hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma.
  • Exemplary bone cancers include, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumors
  • osteogenic sarcoma osteosarcoma
  • fibrosarcoma malignant fibrous histiocytoma
  • chondrosarcoma chondrosarcoma
  • Ewing's sarcoma malignant lymphoma
  • multiple myeloma malignant giant cell tumor chordoma
  • osteochronfroma osteocart
  • Exemplary nervous system cancers include cancers of the skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, meduoblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma, glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors, neuro-ectodermal tumors), and spinal cord (neurofibroma, meningioma, glioma, sarcoma), neuroblastoma, Lhermitte-Duclos disease and pineal tumors.
  • skull osteoma, hemangioma, granuloma,
  • Exemplary gynecological cancers include cancers of the breast (ductal carcinoma, lobular carcinoma, breast sarcoma, triple-negative breast cancer, HER2-positive breast cancer, inflammatory breast cancer, papillary carcinoma), uterus (endometrial carcinoma), cervix (cervical carcinoma, pre -tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), and fallopian tubes (car
  • Exemplary skin cancers include melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, Merkel cell skin cancer, moles dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids.
  • Exemplary head and neck cancers include glioblastoma, melanoma, rhabdosarcoma, lymphosarcoma, osteosarcoma, squamous cell carcinomas, adenocarcinomas, oral cancer, laryngeal cancer, nasopharyngeal cancer, nasal and paranasal cancers, thyroid and parathyroid cancers, tumors of the eye, tumors of the lips and mouth and squamous head and neck cancer.
  • the compounds of the present disclosure can also be useful in the inhibition of tumor metastasis.
  • the compounds of the invention are useful in the treatment of skeletal and chondrocyte disorders including, but not limited to, achrondroplasia, hypochondroplasia, dwarfism, thanatophoric dysplasia (TD) (clinical forms TD I and TD II), Apert syndrome, Crouzon syndrome, Jackson- Weiss syndrome, Beare- Stevenson cutis gyrate syndrome, Pfeiffer syndrome, and craniosynostosis syndromes.
  • the present disclosure provides a method for treating a patient suffering from a skeletal and chondrocyte disorder.
  • compounds described herein can be used to treat Alzheimer’s disease, HIV, or tuberculosis.
  • 8p11 myeloproliferative syndrome refers to myeloid/lymphoid neoplasms associated with eosinophilia and abnormalities of FGFR1.
  • an ex vivo cell refers to a cell that is in vitro, ex vivo or in vivo.
  • an ex vivo cell can be part of a tissue sample excised from an organism such as a mammal.
  • an in vitro cell can be a cell in a cell culture.
  • an in vivo cell is a cell living in an organism such as a mammal.
  • contacting refers to the bringing together of indicated moieties in an in vitro system or an in vivo system.
  • “contacting” KRAS with a compound described herein includes the administration of a compound described herein to an individual or patient, such as a human, having KRAS, as well as, for example, introducing a compound described herein into a sample containing a cellular or purified preparation containing KRAS.
  • the term “individual,” “subject,” or “patient,” used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
  • terapéuticaally effective amount refers to the amount of active compound or pharmaceutical agent such as an amount of any of the solid forms or salts thereof as disclosed herein that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
  • An appropriate “effective” amount in any individual case may be determined using techniques known to a person skilled in the art.
  • pharmaceutically acceptable is used herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, immunogenicity or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • phrases “pharmaceutically acceptable carrier or excipient” refers to a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, or encapsulating material. Excipients or carriers are generally safe, nontoxic and neither biologically nor otherwise undesirable and include excipients or carriers that are acceptable for veterinary use as well as human pharmaceutical use. In one embodiment, each component is “pharmaceutically acceptable” as defined herein.
  • treating refers to inhibiting a disease; for example, inhibiting a disease, condition, or disorder in an individual who is experiencing or displaying the pathology or symptomology of the disease, condition, or disorder (/.e., arresting further development of the pathology and/or symptomology) or ameliorating the disease; for example, ameliorating a disease, condition, or disorder in an individual who is experiencing or displaying the pathology or symptomology of the disease, condition, or disorder (/.e., reversing the pathology and/or symptomology) such as decreasing the severity of the disease.
  • prevent comprises the prevention of at least one symptom associated with or caused by the state, disease or disorder being prevented.
  • Compounds of the present disclosure may be useful in treatment of cancer when used in combination with one or more additional pharmaceutical agents agents, as described in further detail below.
  • Cancer cell growth and survival can be impacted by dysfunction in multiple signaling pathways.
  • Targeting more than one signaling pathway (or more than one biological molecule involved in a given signaling pathway) may reduce the likelihood of drug-resistance arising in a cell population, and/or reduce the toxicity of treatment.
  • One or more additional pharmaceutical agents such as, for example, chemotherapeutics, anti-inflammatory agents, steroids, immunosuppressants, immune- oncology agents, metabolic enzyme inhibitors, chemokine receptor inhibitors, and phosphatase inhibitors, as well as targeted therapies such as Bcr-Abl, Flt-3, EGFR, HER2, JAK, c-MET, VEGFR, PDGFR, c-Kit, IGF-1 R, RAF, FAK, and CDK4/6 kinase inhibitors such as, for example, those described in WO 2006/056399 can be used in combination with the compounds of the present disclosure for treatment of KRAS-associated diseases, disorders or conditions.
  • Other agents such as therapeutic antibodies can be used in combination with the compounds of the present disclosure for treatment of KRAS-associated diseases, disorders or conditions.
  • the one or more additional pharmaceutical agents can be administered to a patient simultaneously or sequentially.
  • the KRAS inhibitor is administered or used in combination with a BCL2 inhibitor or a CDK4/6 inhibitor.
  • the compounds as disclosed herein can be used in combination with one or more other enzyme/protein/receptor inhibitors therapies for the treatment of diseases, such as cancer and other diseases or disorders described herein.
  • diseases and indications treatable with combination therapies include those as described herein.
  • cancers include solid tumors and non-solid tumors, such as liquid tumors, blood cancers.
  • infections include viral infections, bacterial infections, fungus infections or parasite infections.
  • the compounds of the present disclosure can be combined with one or more inhibitors of the following kinases for the treatment of cancer: Akt1 , Akt2, Akt3, BCL2, CDK4/6, TGF-pR, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IDH2, IGF-1 R, IR- R, PDGFaR, PDGFpR, PI3K (alpha, beta, gamma, delta, and multiple or selective), CSF1R, KIT, FLK-II, KDR/FLK-1, FLK-4, flt-1 , FGFR1, FGFR2, FGFR3, FGFR4, c-Met, PARP, Ron, Sea, TRKA, TRKB, TRKC, TAM kinases (Axl, Mer, Tyro3), FLT3, VEGFR/
  • the compounds of the present disclosure can be combined with one or more of the following inhibitors for the treatment of cancer or infections.
  • inhibitors that can be combined with the compounds of the present disclosure for treatment of cancer and infections include an FGFR inhibitor (FGFR1, FGFR2, FGFR3 or FGFR4, e.g., pemigatinib (INCB54828), INCB62079), an EGFR inhibitor (also known as ErB-1 or HER-1; e.g., erlotinib, gefitinib, vandetanib, orsimertinib, cetuximab, necitumumab, or panitumumab), a VEGFR inhibitor or pathway blocker (e.g.
  • a PARP inhibitor e.g., olaparib, rucaparib, veliparib or niraparib
  • a JAK inhibitor e.g., ruxolitinib or baricitinib; or JAK1; e.g., itacitinib (INCB39110), INCB052793, or INCB054707)
  • an IDO inhibitor e.g., epacadostat, NLG919, or BMS-986205, MK7162
  • an LSD1 inhibitor e.g., GSK2979552, INCB59872 and INC
  • the compound or salt described herein is administered with a PI3K5 inhibitor. In some embodiments, the compound or salt described herein is administered with a JAK inhibitor. In some embodiments, the compound or salt described herein is administered with a JAK1 or JAK2 inhibitor (e.g., baricitinib or ruxolitinib). In some embodiments, the compound or salt described herein is administered with a JAK1 inhibitor. In some embodiments, the compound or salt described herein is administered with a JAK1 inhibitor, which is selective over JAK2.
  • Example antibodies for use in combination therapy include, but are not limited to, trastuzumab (e.g., anti-HER2), ranibizumab (e.g., anti-VEGF-A), bevacizumab (AVASTINTM, e.g., anti-VEGF), panitumumab (e.g., anti-EGFR), cetuximab (e.g., anti-EGFR), rituxan (e.g., anti-CD20), and antibodies directed to c-MET.
  • trastuzumab e.g., anti-HER2
  • ranibizumab e.g., anti-VEGF-A
  • bevacizumab AVASTINTM, e.g., anti-VEGF
  • panitumumab e.g., anti-EGFR
  • cetuximab e.g., anti-EGFR
  • rituxan e.g., anti-CD20
  • a cytostatic agent cisplatin, doxorubicin, taxotere, taxol, etoposide, irinotecan, camptosar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methotrexate, temozolomide, cyclophosphamide, SCH 66336, R115777, L778.123, BMS 214662, I RESSATM(gefitinib), TARCEVATM (erlotinib), antibodies to EGFR, intron, ara-C, adriamycin, cytoxan, gemcitabine, uracil mustard, chlormethine, ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine, triethylenethio
  • the compounds of the present disclosure can further be used in combination with other methods of treating cancers, for example by chemotherapy, irradiation therapy, tumor- targeted therapy, adjuvant therapy, immunotherapy or surgery.
  • immunotherapy include cytokine treatment (e.g., interferons, GM-CSF, G-CSF, IL-2), CRS-207 immunotherapy, cancer vaccine, monoclonal antibody, bispecific or multi-specific antibody, antibody drug conjugate, adoptive T cell transfer, Toll receptor agonists, RIG-I agonists, oncolytic virotherapy and immunomodulating small molecules, including thalidomide or JAK1/2 inhibitor, PI3K5 inhibitor and the like.
  • cytokine treatment e.g., interferons, GM-CSF, G-CSF, IL-2
  • CRS-207 immunotherapy cancer vaccine
  • monoclonal antibody bispecific or multi-specific antibody
  • antibody drug conjugate adoptive T cell transfer
  • Toll receptor agonists e.g., RIG-I
  • the compounds can be administered in combination with one or more anti-cancer drugs, such as a chemotherapeutic agent.
  • chemotherapeutics include any of: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bevacizumab, bexarotene, baricitinib, bleomycin, bortezomib, busulfan intravenous, busulfan oral, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, decitabine,
  • chemotherapeutics include proteasome inhibitors (e.g., bortezomib), thalidomide, revlimid, and DNA-damaging agents such as melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide, carmustine, and the like.
  • proteasome inhibitors e.g., bortezomib
  • thalidomide thalidomide
  • revlimid thalidomide
  • DNA-damaging agents such as melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide, carmustine, and the like.
  • Example steroids include corticosteroids such as dexamethasone or prednisone.
  • Example Bcr-Abl inhibitors include imatinib mesylate (GLEEVACTM), nilotinib, dasatinib, bosutinib, and ponatinib, and pharmaceutically acceptable salts.
  • Other example suitable Bcr-Abl inhibitors include the compounds, and pharmaceutically acceptable salts thereof, of the genera and species disclosed in U.S. Pat. No. 5,521 ,184, WO 04/005281 , and U.S. Pat. No. 7,745,437.
  • Example suitable Flt-3 inhibitors include midostaurin, lestaurtinib, linifanib, sunitinib, sunitinib, maleate, sorafenib, quizartinib, crenolanib, pacritinib, tandutinib, PLX3397 and ASP2215, and their pharmaceutically acceptable salts.
  • Other example suitable Flt-3 inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 03/037347, WO 03/099771 , and WO 04/046120.
  • Example suitable RAF inhibitors include dabrafenib, sorafenib, and vemurafenib, and their pharmaceutically acceptable salts.
  • Other example suitable RAF inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 00/09495 and WO 05/028444.
  • Example suitable FAK inhibitors include VS-4718, VS-5095, VS-6062, VS-6063, BI853520, and GSK2256098, and their pharmaceutically acceptable salts.
  • FAK inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 04/080980, WO 04/056786, WO 03/024967, WO 01/064655, WO 00/053595, and WO 01/014402.
  • Example suitable CDK4/6 inhibitors include palbociclib, ribociclib, trilaciclib, lerociclib, and abemaciclib, and their pharmaceutically acceptable salts.
  • Other example suitable CDK4/6 inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 09/085185, WO 12/129344, WO 11/101409, WO 03/062236, WO 10/075074, and WO 12/061156.
  • the compounds of the disclosure can be used in combination with one or more other kinase inhibitors including imatinib, particularly for treating patients resistant to imatinib or other kinase inhibitors.
  • the compounds of the disclosure can be used in combination with a chemotherapeutic in the treatment of cancer and may improve the treatment response as compared to the response to the chemotherapeutic agent alone, without exacerbation of its toxic effects.
  • the compounds of the disclosure can be used in combination with a chemotherapeutic provided herein.
  • additional pharmaceutical agents used in the treatment of multiple myeloma can include, without limitation, melphalan, melphalan plus prednisone [MP], doxorubicin, dexamethasone, and Velcade (bortezomib).
  • the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent.
  • an alkylating agent include cyclophosphamide (CY), melphalan (MEL), and bendamustine.
  • the proteasome inhibitor is carfilzomib.
  • the corticosteroid is dexamethasone (DEX).
  • the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM). Additive or synergistic effects are desirable outcomes of combining a CDK2 inhibitor of the present disclosure with an additional agent.
  • the agents can be combined with the present compound in a single or continuous dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.
  • the compounds of the present disclosure can be used in combination with one or more other inhibitors or one or more therapies for the treatment of infections.
  • infections include viral infections, bacterial infections, fungus infections or parasite infections.
  • a corticosteroid such as dexamethasone is administered to a patient in combination with the compounds of the disclosure where the dexamethasone is administered intermittently as opposed to continuously.
  • the compounds of Formula (I) or any of the embodiments thereof as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be combined with another immunogenic agent, such as cancerous cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells, and cells transfected with genes encoding immune stimulating cytokines.
  • tumor vaccines include peptides of melanoma antigens, such as peptides of gp1OO, MAGE antigens, Trp-2, MARTI and/or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF.
  • tumor vaccines include the proteins from viruses implicated in human cancers such as Human Papilloma Viruses (HPV), Hepatitis Viruses (HBV and HCV) and Kaposi's Herpes Sarcoma Virus (KHSV).
  • HPV Human Papilloma Viruses
  • HBV and HCV Hepatitis Viruses
  • KHSV Kaposi's Herpes Sarcoma Virus
  • the compounds of the present disclosure can be used in combination with tumor specific antigen such as heat shock proteins isolated from tumor tissue itself.
  • the compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be combined with dendritic cells immunization to activate potent anti-tumor responses.
  • the compounds of the present disclosure can be used in combination with bispecific macrocyclic peptides that target Fe alpha or Fe gamma receptor-expressing effectors cells to tumor cells.
  • the compounds of the present disclosure can also be combined with macrocyclic peptides that activate host immune responsiveness.
  • combinations of the compounds of the disclosure with other therapeutic agents can be administered to a patient prior to, during, and/or after a bone marrow transplant or stem cell transplant.
  • the compounds of the present disclosure can be used in combination with bone marrow transplant for the treatment of a variety of tumors of hematopoietic origin.
  • the compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be used in combination with vaccines, to stimulate the immune response to pathogens, toxins, and self-antigens.
  • pathogens for which this therapeutic approach may be particularly useful include pathogens for which there is currently no effective vaccine, or pathogens for which conventional vaccines are less than completely effective. These include, but are not limited to, HIV, Hepatitis (A, B, & C), Influenza, Herpes, Giardia, Malaria, Leishmania, Staphylococcus aureus, Pseudomonas Aeruginosa.
  • Viruses causing infections treatable by methods of the present disclosure include, but are not limit to human papillomavirus, influenza, hepatitis A, B, C or D viruses, adenovirus, poxvirus, herpes simplex viruses, human cytomegalovirus, severe acute respiratory syndrome virus, Ebola virus, measles virus, herpes virus (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein Barr virus), flaviviruses, echovirus, rhinovirus, coxsackie virus, cornovirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis virus.
  • human papillomavirus influenza, hepatitis A, B
  • Pathogenic bacteria causing infections treatable by methods of the disclosure include, but are not limited to, chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumococci, meningococci and conococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme's disease bacteria.
  • Pathogenic fungi causing infections treatable by methods of the disclosure include, but are not limited to, Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus (fumigatus, niger, etc.), Genus Mucorales (mucor, absidia, rhizophus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis and Histoplasma capsulatum.
  • Candida albicans, krusei, glabrata, tropicalis, etc.
  • Cryptococcus neoformans Aspergillus (fumigatus, niger, etc.)
  • Genus Mucorales micor, absidia, rhizophus
  • Sporothrix schenkii Blastomyces dermatitidis
  • Paracoccidioides brasiliensis C
  • Pathogenic parasites causing infections treatable by methods of the disclosure include, but are not limited to, Entamoeba histolytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, and Nippostrongylus brasiliensis.
  • more than one pharmaceutical agent When more than one pharmaceutical agent is administered to a patient, they can be administered simultaneously, separately, sequentially, or in combination (e.g., for more than two agents).
  • immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CBL-B, CD20, CD28, CD40, CD70, CD122, CD96, CD73, CD47, CDK2, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, HPK1 , CD137 (also known as 4-1 BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, TLR (TLR7/8), TIGIT, CD112R, VISTA, PD-1 , PD-L1 and PD-L2.
  • immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CBL-B, CD20, CD28, CD40, CD70, CD122, CD96, CD73, CD47, CDK2, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, HPK1
  • the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, 0X40, GITR and CD137.
  • the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, TIGIT, and VISTA.
  • the compounds provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors and TGFR beta inhibitors.
  • the compounds provided herein can be used in combination with one or more agonists of immune checkpoint molecules, e.g., 0X40, CD27, GITR, and CD137 (also known as 4-1 BB).
  • one or more agonists of immune checkpoint molecules e.g., 0X40, CD27, GITR, and CD137 (also known as 4-1 BB).
  • the inhibitor of an immune checkpoint molecule is anti-PD1 antibody, anti-PD-L1 antibody, or anti-CTLA-4 antibody.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1 or PD-L1 , e.g., an anti-PD-1 or anti-PD-L1 monoclonal antibody.
  • the anti-PD-1 or anti-PD-L1 antibody is nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, cemiplimab, atezolizumab, avelumab, tislelizumab, spartalizumab (PDR001), cetrelimab (JNJ-63723283), toripalimab (JS001), camrelizumab (SHR-1210), sintilimab (IBI308), AB122 (GLS-010), AMP-224, AMP-514/MEDI-0680, BMS936559, JTX-4014, BGB-108, SHR-1210, MEDI4736, FAZ053, B
  • the inhibitor of PD-1 or PD-L1 is one disclosed in U.S. Pat. Nos. 7,488,802, 7,943,743, 8,008,449, 8,168,757, 8,217, 149, or 10,308,644; U.S. Publ. Nos.
  • the inhibitor of PD-L1 is INCB086550.
  • the PD-L1 inhibitor is selected from the compounds in Table A, or a pharmaceutically acceptable salt thereof.
  • Table A is selected from the compounds in Table A, or a pharmaceutically acceptable salt thereof.
  • the antibody is an anti-PD-1 antibody, e.g., an anti-PD-1 monoclonal antibody.
  • the anti-PD-1 antibody is nivolumab, pembrolizumab, cemiplimab, spartalizumab, camrelizumab, cetrelimab, toripalimab, sintilimab, AB122, AMP-224, JTX-4014, BGB-108, BCD-100, BAT1306, LZM009, AK105, HLX10, or TSR-042.
  • the anti-PD-1 antibody is nivolumab, pembrolizumab, cemiplimab, spartalizumab, camrelizumab, cetrelimab, toripalimab, or sintilimab.
  • the anti-PD-1 antibody is pembrolizumab.
  • the anti-PD-1 antibody is nivolumab.
  • the anti-PD-1 antibody is cemiplimab.
  • the anti-PD-1 antibody is spartalizumab.
  • the anti-PD-1 antibody is camrelizumab.
  • the anti-PD-1 antibody is cetrelimab.
  • the anti-PD-1 antibody is toripalimab. In some embodiments, the anti-PD-1 antibody is sintilimab. In some embodiments, the anti-PD-1 antibody is AB122. In some embodiments, the anti-PD-1 antibody is AMP-224. In some embodiments, the anti-PD-1 antibody is JTX-4014. In some embodiments, the anti-PD-1 antibody is BGB-108. In some embodiments, the anti-PD-1 antibody is BCD-100. In some embodiments, the anti-PD-1 antibody is BAT1306. In some embodiments, the anti-PD-1 antibody is LZM009. In some embodiments, the anti-PD-1 antibody is AK105. In some embodiments, the anti-PD-1 antibody is HLX10.
  • the anti-PD-1 antibody is TSR-042.
  • the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab.
  • the anti-PD-1 monoclonal antibody is MGA012 (INCMGA0012; retifanlimab).
  • the anti-PD1 antibody is SHR-1210.
  • Other anti-cancer agent(s) include antibody therapeutics such as 4-1 BB (e.g., urelumab, utomilumab).
  • the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, e.g., an anti-PD-L1 monoclonal antibody.
  • the anti-PD-L1 monoclonal antibody is atezolizumab, avelumab, durvalumab, tislelizumab, BMS-935559, MEDI4736, atezolizumab (MPDL3280A; also known as RG7446), avelumab (MSB0010718C), FAZ053, KN035, CS1001 , SHR-1316, CBT-502, A167, STI-A101 , CK-301, BGB-A333, MSB-2311 , HLX20, or LY3300054.
  • the anti-PD-L1 antibody is atezolizumab, avelumab, durvalumab, or tislelizumab. In some embodiments, the anti-PD-L1 antibody is atezolizumab. In some embodiments, the anti-PD-L1 antibody is avelumab. In some embodiments, the anti-PD-L1 antibody is durvalumab. In some embodiments, the anti-PD-L1 antibody is tislelizumab. In some embodiments, the anti-PD-L1 antibody is BMS-935559. In some embodiments, the anti-PD-L1 antibody is MEDI4736. In some embodiments, the anti-PD-L1 antibody is FAZ053.
  • the anti-PD-L1 antibody is KN035. In some embodiments, the anti-PD-L1 antibody is CS1001. In some embodiments, the anti-PD-L1 antibody is SHR- 1316. In some embodiments, the anti-PD-L1 antibody is CBT-502. In some embodiments, the anti-PD-L1 antibody is A167. In some embodiments, the anti-PD-L1 antibody is STI- A101. In some embodiments, the anti-PD-L1 antibody is CK-301. In some embodiments, the anti-PD-L1 antibody is BGB-A333. In some embodiments, the anti-PD-L1 antibody is MSB- 2311. In some embodiments, the anti-PD-L1 antibody is HLX20. In some embodiments, the anti-PD-L1 antibody is LY3300054.
  • the inhibitor of an immune checkpoint molecule is a small molecule that binds to PD-L1, or a pharmaceutically acceptable salt thereof. In some embodiments, the inhibitor of an immune checkpoint molecule is a small molecule that binds to and internalizes PD-L1, or a pharmaceutically acceptable salt thereof. In some embodiments, the inhibitor of an immune checkpoint molecule is a compound selected from those in US 2018/0179201 , US 2018/0179197, US 2018/0179179, US 2018/0179202, US 2018/0177784, US 2018/0177870, US 2019/0300524, and US 2019/0345170, or a pharmaceutically acceptable salt thereof, each of which is incorporated herein by reference in its entirety.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of KIR, TIGIT, LAIR1 , CD160, 2B4 and TGFR beta.
  • the inhibitor is MCLA-145.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody.
  • the anti-CTLA-4 antibody is ipilimumab, tremelimumab, AGEN1884, or CP-675,206.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody.
  • the anti-LAG3 antibody is BMS-986016, LAG525, INCAGN2385, or eftilagimod alpha (IMP321).
  • the inhibitor of an immune checkpoint molecule is an inhibitor of CD73. In some embodiments, the inhibitor of CD73 is oleclumab.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of TIGIT. In some embodiments, the inhibitor of TIGIT is OMP-31M32. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of VISTA. In some embodiments, the inhibitor of VISTA is JNJ-61610588 or CA-170.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of B7-H3.
  • the inhibitor of B7-H3 is enoblituzumab, MGD009, or 8H9.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of KIR.
  • the inhibitor of KIR is lirilumab or IPH4102.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of A2aR. In some embodiments, the inhibitor of A2aR is CPI-444.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of TGF-beta.
  • the inhibitor of TGF-beta is trabedersen, galusertinib, or M7824.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of PI3K-gamma. In some embodiments, the inhibitor of PI3K-gamma is I PI-549.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of CD47.
  • the inhibitor of CD47 is Hu5F9-G4 or TTI-621.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of CD73. In some embodiments, the inhibitor of CD73 is MEDI9447.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of CD70.
  • the inhibitor of CD70 is cusatuzumab or BMS-936561.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of TIM3, e.g., an anti-TIM3 antibody.
  • the anti-TIM3 antibody is INCAGN2390, MBG453, or TSR-022.
  • the inhibitor of an immune checkpoint molecule is an inhibitor of CD20, e.g., an anti-CD20 antibody.
  • the anti-CD20 antibody is obinutuzumab or rituximab.
  • the agonist of an immune checkpoint molecule is an agonist of 0X40, CD27, CD28, GITR, ICOS, CD40, TLR7/8, and CD137 (also known as 4-1 BB).
  • the agonist of CD137 is urelumab. In some embodiments, the agonist of CD137 is utomilumab.
  • the agonist of an immune checkpoint molecule is an inhibitor of GITR.
  • the agonist of GITR is TRX518, MK-4166, INCAGN1876, MK-1248, AMG228, BMS-986156, GWN323, MEDI1873, or MEDI6469.ln some embodiments, the agonist of an immune checkpoint molecule is an agonist of 0X40, e.g., 0X40 agonist antibody or OX40L fusion protein.
  • the anti-OX40 antibody is INCAGN01949, MEDI0562 (tavolimab), MOXR-0916, PF-04518600, GSK3174998, BMS-986178, or 9B12.
  • the OX40L fusion protein is MEDI6383.
  • the agonist of an immune checkpoint molecule is an agonist of CD40.
  • the agonist of CD40 is CP-870893, ADC-1013, CDX-1140, SEA-CD40, R07009789, JNJ-64457107, APX-005M, or Chi Lob 7/4.
  • the agonist of an immune checkpoint molecule is an agonist of ICOS.
  • the agonist of ICOS is GSK-3359609, JTX-2011, or MEDI- 570.
  • the agonist of an immune checkpoint molecule is an agonist of CD28. In some embodiments, the agonist of CD28 is theralizumab.
  • the agonist of an immune checkpoint molecule is an agonist of CD27. In some embodiments, the agonist of CD27 is varlilumab.
  • the agonist of an immune checkpoint molecule is an agonist of TLR7/8. In some embodiments, the agonist of TLR7/8 is MEDI9197.
  • the compounds of the present disclosure can be used in combination with bispecific antibodies.
  • one of the domains of the bispecific antibody targets PD- 1 , PD-L1, CTLA-4, GITR, 0X40, TIM3, LAG3, CD137, ICOS, CD3 or TGFp receptor.
  • the bispecific antibody binds to PD-1 and PD-L1.
  • the bispecific antibody that binds to PD-1 and PD-L1 is MCLA-136.
  • the bispecific antibody binds to PD-L1 and CTLA-4.
  • the bispecific antibody that binds to PD-L1 and CTLA-4 is AK104.
  • the compounds of the disclosure can be used in combination with one or more metabolic enzyme inhibitors.
  • the metabolic enzyme inhibitor is an inhibitor of I DO1 , TDO, or arginase.
  • IDO1 inhibitors include epacadostat, NLG919, BMS-986205, PF-06840003, IOM2983, RG-70099 and LY338196.
  • Inhibitors of arginase inhibitors include INCB1158.
  • the additional compounds, inhibitors, agents, etc. can be combined with the present compound in a single or continuous dosage form, or they can be administered simultaneously or sequentially as separate dosage forms.
  • the compounds of the present disclosure can be administered in the form of pharmaceutical compositions.
  • the present disclosure provides a composition comprising a compound of Formula I, or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or a pharmaceutically acceptable salt thereof, or any of the embodiments thereof, and at least one pharmaceutically acceptable carrier or excipient.
  • These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is indicated and upon the area to be treated.
  • Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral.
  • Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.
  • Parenteral administration can be in the form of a single bolus dose, or may be, e.g., by a continuous perfusion pump.
  • compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
  • Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
  • compositions which contain, as the active ingredient, the compound of the present disclosure or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carriers or excipients.
  • the composition is suitable for topical administration.
  • the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, e.g., a capsule, sachet, paper, or other container.
  • the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, e.g., up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
  • the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g., about 40 mesh.
  • the compounds of the invention may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types.
  • Finely divided (nanoparticulate) preparations of the compounds of the invention can be prepared by processes known in the art see, e.g., WO 2002/000196.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methyl cellulose.
  • the formulations can additionally include: lubricating agents such as talc, magnesium stearate and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
  • the compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
  • the pharmaceutical composition comprises silicified microcrystalline cellulose (SMCC) and at least one compound described herein, or a pharmaceutically acceptable salt thereof.
  • SMCC silicified microcrystalline cellulose
  • the silicified microcrystalline cellulose comprises about 98% microcrystalline cellulose and about 2% silicon dioxide w/w.
  • the composition is a sustained release composition comprising at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.
  • the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one component selected from microcrystalline cellulose, lactose monohydrate, hydroxypropyl methylcellulose and polyethylene oxide.
  • the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and hydroxypropyl methylcellulose.
  • the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and polyethylene oxide.
  • the composition further comprises magnesium stearate or silicon dioxide.
  • the microcrystalline cellulose is Avicel PH102TM.
  • the lactose monohydrate is Fast-flo 316TM.
  • the hydroxypropyl methylcellulose is hydroxypropyl methylcellulose 2208 K4M (e.g., Methocel K4 M PremierTM) and/or hydroxypropyl methylcellulose 2208 K100LV (e.g., Methocel K00LVTM).
  • the polyethylene oxide is polyethylene oxide WSR 1105 (e.g., Polyox WSR 1105TM).
  • a wet granulation process is used to produce the composition. In some embodiments, a dry granulation process is used to produce the composition.
  • compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 1,000 mg (1 g), more usually about 100 mg to about 500 mg, of the active ingredient. In some embodiments, each dosage contains about 10 mg of the active ingredient. In some embodiments, each dosage contains about 50 mg of the active ingredient. In some embodiments, each dosage contains about 25 mg of the active ingredient.
  • unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
  • the components used to formulate the pharmaceutical compositions are of high purity and are substantially free of potentially harmful contaminants (e.g., at least National Food grade, generally at least analytical grade, and more typically at least pharmaceutical grade).
  • the composition is preferably manufactured or formulated under Good Manufacturing Practice standards as defined in the applicable regulations of the U.S. Food and Drug Administration.
  • suitable formulations may be sterile and/or substantially isotonic and/or in full compliance with all Good Manufacturing Practice regulations of the U.S. Food and Drug Administration.
  • the active compound may be effective over a wide dosage range and is generally administered in a therapeutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms and the like.
  • the therapeutic dosage of a compound of the present invention can vary according to, e.g., the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician.
  • the proportion or concentration of a compound of the invention in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration.
  • the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 pg/kg to about 1 g/kg of body weight per day.
  • the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day.
  • the dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
  • the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, e.g., about 0.1 to about 1000 mg of the active ingredient of the present invention.
  • the tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
  • liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
  • compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
  • the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
  • the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
  • Compositions can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face mask, tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.
  • Topical formulations can contain one or more conventional carriers.
  • ointments can contain water and one or more hydrophobic carriers selected from, e.g., liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white Vaseline, and the like.
  • Carrier compositions of creams can be based on water in combination with glycerol and one or more other components, e.g., glycerinemonostearate, PEG- glycerinemonostearate and cetylstearyl alcohol.
  • Gels can be formulated using isopropyl alcohol and water, suitably in combination with other components such as, e.g., glycerol, hydroxyethyl cellulose, and the like.
  • topical formulations contain at least about 0.1 , at least about 0.25, at least about 0.5, at least about 1 , at least about 2 or at least about 5 wt % of the compound of the invention.
  • the topical formulations can be suitably packaged in tubes of, e.g., 100 g which are optionally associated with instructions for the treatment of the select indication, e.g., psoriasis or other skin condition.
  • compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient and the like.
  • compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration.
  • the pH of the compound preparations typically will be between 3 and 11 , more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers or stabilizers will result in the formation of pharmaceutical salts.
  • the therapeutic dosage of a compound of the present invention can vary according to, e.g., the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician.
  • the proportion or concentration of a compound of the invention in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration.
  • the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 pg/kg to about 1 g/kg of body weight per day.
  • the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day.
  • the dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems. V. Labeled Compounds and Assay Methods
  • Another aspect of the present invention relates to labeled compounds of the disclosure (radio-labeled, fluorescent-labeled, etc.) that would be useful not only in imaging techniques but also in assays, both in vitro and in vivo, for localizing and quantitating KRAS protein in tissue samples, including human, and for identifying KRAS ligands by inhibition binding of a labeled compound.
  • Substitution of one or more of the atoms of the compounds of the present disclosure can also be useful in generating differentiated ADME (Adsorption, Distribution, Metabolism and Excretion).
  • the present invention includes KRAS binding assays that contain such labeled or substituted compounds.
  • the present disclosure further includes isotopically-labeled compounds of the disclosure.
  • An “isotopically” or “radio-labeled” compound is a compound of the disclosure where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e. , naturally occurring).
  • Suitable radionuclides that may be incorporated in compounds of the present disclosure include but are not limited to 2 H (also written as D for deuterium), 3 H (also written as T for tritium), 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 0, 18 F, 35 S, 36 CI, 82 Br, 75 Br, 76 Br, 77 Br, 123 l, 124 l, 125 l and 131 1.
  • one or more hydrogen atoms in a compound of the present disclosure can be replaced by deuterium atoms (e.g., one or more hydrogen atoms of a Ci-6 alkyl group of Formula I, II, or any formulae provided herein can be optionally substituted with deuterium atoms, such as -CD3 being substituted for -CHs).
  • deuterium atoms e.g., one or more hydrogen atoms of a Ci-6 alkyl group of Formula I, II, or any formulae provided herein can be optionally substituted with deuterium atoms, such as -CD3 being substituted for -CHs.
  • alkyl groups in Formula I, II, or any formulae provided herein can be perdeuterated.
  • the compound includes at least one deuterium atom.
  • the compound includes two or more deuterium atoms.
  • the compound includes 1-2, 1-3, 1-4, 1-5, or 1-6 deuterium atoms.
  • all of the hydrogen atoms in a compound can be replaced or substituted by deuterium atoms.
  • substitution with heavier isotopes may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances, (see e.g., A. Kerekes et. al. J. Med. Chem. 2011 , 54, 201-210; R. Xu et. al. J. Label Compd. Radiopharm. 2015, 58, 308-312).
  • substitution at one or more metabolism sites may afford one or more of the therapeutic advantages.
  • radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro adenosine receptor labeling and competition assays, compounds that incorporate 3 H, 14 C, 82 Br, 125 l, 131 l or 35 S can be useful. For radio-imaging applications 11 C, 18 F, 125 l, 123 l, 124 l, 131 l, 75 Br, 76 Br or 77 Br can be useful.
  • a “radio-labeled” or “labeled compound” is a compound that has incorporated at least one radionuclide.
  • the radionuclide is selected from 3 H, 14 C, 125 l, 35 S and 82 Br.
  • the present disclosure can further include synthetic methods for incorporating radioisotopes into compounds of the disclosure. Synthetic methods for incorporating radioisotopes into organic compounds are well known in the art, and an ordinary skill in the art will readily recognize the methods applicable for the compounds of disclosure.
  • a labeled compound of the invention can be used in a screening assay to identify and/or evaluate compounds.
  • a newly synthesized or identified compound (/.e., test compound) which is labeled can be evaluated for its ability to bind a KRAS protein by monitoring its concentration variation when contacting with the KRAS, through tracking of the labeling.
  • a test compound (labeled) can be evaluated for its ability to reduce binding of another compound which is known to bind to a KRAS protein (/.e., standard compound). Accordingly, the ability of a test compound to compete with the standard compound for binding to the KRAS protein directly correlates to its binding affinity.
  • the standard compound is labeled and test compounds are unlabeled. Accordingly, the concentration of the labeled standard compound is monitored in order to evaluate the competition between the standard compound and the test compound, and the relative binding affinity of the test compound is thus ascertained.
  • kits useful useful, e.g., in the treatment or prevention of diseases or disorders associated with the activity of KRAS, such as cancer or infections, which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, II, or any of the embodiments thereof.
  • kits can further include one or more of various conventional pharmaceutical kit components, such as, e.g., containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art.
  • Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.
  • Preparatory LC-MS purifications of some of the compounds prepared were performed on Waters mass directed fractionation systems.
  • the basic equipment setup, protocols, and control software for the operation of these systems have been described in detail in the literature. See e.g. “Two-Pump At Column Dilution Configuration for Preparative LC-MS”, K. Blom, J. Combi. Chem., 4, 295 (2002); “Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification”, K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi.
  • LCMS analytical liquid chromatography mass spectrometry
  • Triphosgene (9.07 g, 30.6 mmol) was added to a solution of 2-amino-4-bromo-3- fluoro-5-iodobenzoic acid (22g, 61.1 mmol) in dioxane (200 ml) and then the reaction was stirred at 80 °C for 2 h. The reaction mixture was cooled with ice water and then filtered. The solid was washed with EtOAc to provide the desired product as a solid.
  • DI PEA 8.14 ml, 46.6 mmol was added to a mixture of 7-bromo-8-fluoro-6-iodo-3- nitroquinoline-2,4-diol (10 g, 23.31 mmol) in POC (10.86 ml, 117 mmol) and then the reaction was stirred at 100 °C for 2 h. The solvent was removed under vacuum and then azeotroped with toluene 3 times to provide the crude material which was purified with FCC.
  • Step 2 8-(4, 4, 5, 5- Tetramethyl- 1, 3, 2-dioxaborolan-2-yl)- 1, 2, 3, 4-tetrahydronaphthalene- 1- carbonitrile
  • Step 5 methyl (2R,4S)-2-ethynyl-4-(pyridin-2-yloxy)pyrrolidine-1 -carboxylate
  • terf-butyl (2F?,4S)-2-ethynyl-4-(pyridin-2-yloxy)pyrrolidine-1- carboxylate 0.5 g, 1.734 mmol
  • MeCN MeCN
  • 4N HCI in dioxane 4 ml, 16 mmol
  • the residue was partitioned between water and THF and Na2COs (3.7 g, 34.7 mmol) was added.
  • Step 1 tert-Butyl ( 1R,4R,5S)-5-((3-amino-6-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-8-fluoro-2- (methylthio) quinolin-4-yl) (tert-butoxycarbonyl) amino)-2-azabicyclo[2. 1. 1 ]hexane-2- carboxylate
  • Step 4 1-((1S,3R,5S)-3-Ethynyl-2-azabicyclo[3. 1 ,0]hexan-2-yl)ethan-1-one
  • Step 7 3-(7-(2, 3-Dichlorophenyl)-8-fluoro-2, 4-dioxo- 1, 4-dihydro-2H-benzo[d][ 1 ,3]oxazin-6- yl) propanenitrile
  • Step 11 4-(((1R,4R,5S)-2-(tert-Butoxycarbonyl)-2-azabicyclo[2. 1. 1]hexan-5-yl)amino)-2-
  • Step 4 Cyclopropyl((2R,4S)-2-ethynyl-4-fluoropyrrolidin- 1-yl)methanone tert-Butyl (2F?,4S)-2-ethynyl-4-fluoropyrrolidine-1 -carboxylate (2.05 g, 9.61 mmol) was added to 4N HCI in dioxane (9.61 mL, 38.5 mmol) and the solution was stirred at r.t. for 2 h. Upon completion, the volatiles were removed under reduced pressure.
  • Example 2 4-(1-((1/?,4/?,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-6-fluoro-7- (7-fluoronaphthalen-1-yl)-4-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)-1H-pyrrolo[3,2- c]quinolin-2-yl)-/V,/V,1-trimethyl-1H-pyrazole-5-carboxamide Step 1.
  • Step 1 tert-Butyl (1R,4R,5S)-5-(8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((2R,4S)- 1-(methoxycarbonyl)-4-(pyridin-2-yloxy)pyrrolidin-2-yl)-4-(methylthio)-1H-pyrrolo[3,2-
  • the reaction flask was evacuated, back filled with nitrogen, and then stirred at 75 °C for 2 h.
  • the mixture was cooled to r.t. and CS2CO3 (192 mg, 0.589 mmol) was added, then stirred at 100 °C for 2 h.
  • the reaction mixture was quenched with water and a small amount of 30% aq ammonium hydroxide, then extracted with EtOAc.
  • the organic layer was washed with water and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by FCC, eluting with 0-50% EtOAc in DCM to give the product.
  • Example 7 8-(2-((1 S,3R,5S)-2-Acetyl-2-azabicyclo[3.1.0]hexan-3-yl)-1-((1R,4R,5S)-2- azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-8-methyl-4-((S)-1-((S)-1-methylpyrrolidin-2- yl)ethoxy)-1 H-pyrrolo[3,2-c]quinolin-7-yl)-1, 2, 3, 4-tetrahydronaphthalene-1 -carbonitrile
  • Step 4 3-(1-((1R,4R,5S)-2-Azabicyclo[2. 1. 1]hexan-5-yl)-2-((2R,4S)-1- (cyclopropanecarbonyl)-4-(difluoromethoxy)pyrrolidin-2-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4- ((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)-1H-pyrrolo[3,2-c]quinolin-8-yl) propanenitrile
  • reaction mixture was sparged with nitrogen for 5 min then stirred aggressively at 80 °C for 20 h. Upon completion, the reaction mixture was cooled to r.t. , diluted with DCM, and filtered through a diatomaceous earth plug. To the filtrate was added TFA (0.5 mL) and the solution was stirred at r.t. for 30 min. The volatiles were removed under reduced pressure to afford the crude product.
  • the desired product purified by prep-LCMS (XBRIDGE® C18 column, eluting with a gradient of MeCN/water containing 0.1% TFA, at flow rate of 60 mL/min) to afford the product as a pair of atropisomers in the form of an amorphous powder.
  • the desired product purified by prep-LCMS (XBRIDGE® C18 column, eluting with a gradient of MeCN/water containing 0.1% TFA, at flow rate of 60 mL/min) to afford the product as a pair of atropisomers in the form of an amorphous powder.
  • Step 3 3-(1-((1R,4R,5S)-2-Azabicyclo[2. 1. 1]hexan-5-yl)-2-((2R,4S)-1- (cyclopropanecarbonyl)-4-fluoropyrrolidin-2-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-((S)-1-((S)- 1 -methyl pyrrolidin-2-yl) ethoxy) - 1 H-pyrrolo[ 3, 2-c]qu inolin- 8-yl) propanenitrile
  • the desired product purified by prep-LCMS (XBRIDGE® C18 column, eluting with a gradient of MeCN/water containing 0.1% TFA, at flow rate of 60 mL/min) to afford the product as a pair of atropisomers in the form of an amorphous powder.
  • the inhibitor potency of the exemplified compounds was determined in a fluorescence based guanine nucleotide exchange assay, which measures the exchange of bodipy-GDP (fluorescently labeled GDP) for GppNHp (Non-hydrolyzable GTP analog) to generate the active state of KRAS in the presence of SOS1 (guanine nucleotide exchange factor).
  • Inhibitors were serially diluted in DMSO and a volume of 0.1 pL was transferred to the wells of a black low volume 384-well plate.
  • the 10 pL/well reaction concentration of the bodipy-loaded KRAS G12D, GppNHp, and SOS1 were 2.5 nM, 500 uM, and 150 nM, respectively.
  • the reaction plates were incubated at ambient temperature for 2 h, a time estimated for complete GDP-GTP exchange in the absence of inhibitor.
  • Similar guanine nucleotide exchange assays were used with 2.5nM as final concentration for the bodipy loaded KRAS proteins and 3 h incubation after adding GppNHp-SOS1 mixture.
  • a cyclic peptide described to selectively bind G12D mutant (Sakamoto et al., BBRC 484.3 (2017), 605-611) or internal compounds with confirmed binding were used as positive controls in the assay plates. Fluorescence intensities were measured on a PheraStar plate reader instrument (BMG Labtech) with excitation at 485 nm and emission at 520 nm.
  • GraphPad prism or Genedata Screener SmartFit was used to analyze the data.
  • the IC50 values were derived by fitting the data to a four parameter logistic equation producing a sigmoidal dose-response curve with a variable Hill coefficient.
  • the KRAS_G12D and KRAS_G12V exchange assay IC50 data are provided in Table 1 below.
  • the symbol “f” indicates IC50 s 100 nM, “ft” indicates IC50 > 100 nM but ⁇ 1 M; and “ftt” indicates IC50 is >1 M but ⁇ 5 pM, “tttt” indicates IC50 is >5 pM but ⁇ 10 pM.
  • NA indicates IC50 not available.
  • Example B Luminescent Viability Assay
  • MIA PaCa-2 (KRAS G12C; ATCC® CRL-1420), NCI-H358 (KRAS G12C; ATCC® CRL-5807), A427 (KRAS G12D; ATCC® HTB53), HPAFII (KRAS G12D; ATCC® CRL- 1997), YAPC (KRAS G12V; DSMZ ACC382), SW480 (KRAS G12V; ATCC® CRL-228) and NCI-H838 (KRAS WT; ATCC® CRL-5844) cells are cultured in RPMI 1640 media supplemented with 10% FBS (Gibco/Life Technologies).
  • Example C Cellular pERK HTRF Assay
  • MIA PaCa-2 (KRAS G12C; ATCC® CRL-1420), NCI-H358 (KRAS G12C; ATCC® CRL-5807), A427 (KRAS G12D; ATCC® HTB53), HPAFII (KRAS G12D; ATCC® CRL- 1997), YAPC (KRAS G12V; DSMZ ACC382), SW480 (KRAS G12V; ATCC® CRL-228) and NCI-H838 (KRAS WT; ATCC® CRL-5844) cells are purchased from ATCC and maintained in RPMI 1640 media supplemented with 10% FBS (Gibco/Life Technologies).
  • the cells are plated at 5000 cells per well (8 uL) into Greiner 384-well low volume, flat-bottom, and tissue culture treated white plates and incubated overnight at 370 °C, 5% CO2.
  • test compound stock solutions are diluted in media at 3x the final concentration and 4 uL are added to the cells, with a final concentration of 0.1% of DMSO.
  • the cells are incubated with the test compounds for 4 h (G12C and G12V) or 2 hrs (G12D) at 37°C, 5% CO2.
  • Four uL of 4x lysis buffer with blocking reagent (Cisbio) are added to each well and plates are rotated gently (300 rpm) for 30 min. at r.t..
  • Cisbio anti Phospho-ERK 1/2 d2 is mixed with anti Phospho-ERK 1/2 Cryptate (1:1), and added to each well, incubated overnight in the dark at r.t.. Plates are read on the Pherastar plate reader at 665 nm and 620 nm wavelengths. Data are analyzed in Genedata Screener using SmartFit for IC50 values.
  • Example D Whole Blood pERK1/2 HTRF Assay
  • MIA PaCa-2 cells (KRAS G12C; ATCC® CRL-1420), HPAF-II (KRAS G12D; ATCC® CRL-1997) and YAPC (KRAS G12V; DSMZ ACC382) are maintained in RPMI 1640 with 10% FBS (Gibco/Life Technologies).
  • MIA PaCa-2 assay cells are seeded into 96 well tissue culture plates (Corning #3596) at 25000 cells per well in 100 uL media and cultured for 2 days at 37 °C, 5% CO2 before the assay.
  • HPAF-II and YAPC assay cells are seeded in 96 well tissue culture plates at 50000 cells per well in 100 uL media and cultured for 1 day before the assay.
  • Whole Blood are added to the 1uL dots of compounds (prepared in DMSO) in 96 well plates and mixed gently by pipetting up and down so that the concentration of the compound in blood is 1x of desired concentration, in 0.5% DMSO.
  • the media is aspirated from the cells and 50 uL per well of whole blood with test compound is added and incubated for 4 h for MIA PaCa and YAPC assay; or 2 h for HPAF-II assay, respectively at 37 °C, 5% CO2.
  • the plates are gently washed twice by adding PBS to the side of the wells and dumping the PBS from the plate onto a paper towel, tapping the plate to drain well.
  • Fifty ul/well of 1x lysis buffer #1 (Cisbio) with blocking reagent ( Cisbio) and Benzonase nuclease (Sigma Cat # E1014-5KU, 1: 10000 final concentration) is then added and incubated at r.t. for 30 min. with shaking (250 rpm).
  • 16 uL of lysate is transferred into 384-well Greiner small volume white plate using an Assist Plus (Integra Biosciences, NH).
  • the 96-Well Ras Activation ELISA Kit (Cell Biolabs Inc; #STA441) uses the Rafi RBD (Rho binding domain) bound to a 96-well plate to selectively pull down the active form of Ras from cell lysates.
  • the captured GTP-Ras is then detected by a pan- Ras antibody and HRP-conjugated secondary antibody.
  • MIA PaCa-2 KRAS G12C; ATCC® CRL-1420
  • NCI-H358 KRAS G12C; ATCC® CRL-5807
  • A427 KRAS G12D; ATCC® HTB53
  • HPAFII KRAS G12D; ATCC® CRL- 1997)
  • YAPC KRAS G12V; DSMZ ACC382
  • SW480 KRAS G12V; ATCC® CRL-228)
  • NCI-H838 KRAS WT; ATCC® CRL-5844
  • the cells are seeded into 96 well tissue culture plates (Corning #3596) at 25000 cells per well in 100 uL media and cultured for 2 days at 37 °C, 5% CO2 so that they are approximately 80% confluent at the start of the assay.
  • the cells are treated with compounds for either 4 h or overnight at 37 °C, 5% CO2.
  • the cells are washed with PBS, drained well and then lysed with 50 uL of the 1x Lysis buffer (provided by the kit) plus added Halt Protease and Phosphatase inhibitors (1:100) for 1 h on ice.
  • the Raf-1 RBD is diluted 1:500 in Assay Diluent (provided in kit) and 100 pL of the diluted Raf-1 RBD is added to each well of the Raf-1 RBD Capture Plate.
  • the plate is covered with a plate sealing film and incubated at r.t. for 1 h on an orbital shaker.
  • the plate is washed 3 times with 250 pL 1X Wash Buffer per well with thorough aspiration between each wash.
  • 50 pL of Ras lysate sample (10-100 pg) is added per well in duplicate.
  • a “no cell lysate” control is added in a couple of wells for background determination.
  • Assay Diluent 50 pL of Assay Diluent is added to all wells immediately to each well and the plate is incubated at r.t. for 1 h on an orbital shaker. The plate is washed 5 times with 250 pL 1X Wash Buffer per well with thorough aspiration between each wash. 100 pL of the diluted Anti-pan-Ras Antibody is added to each well and the plate is incubated at r.t. for 1 h on an orbital shaker. The plate is washed 5 times as previously. 100 pL of the diluted Secondary Antibody, HRP Conjugate is added to each well and the plate is incubated at r.t. for 1 h on an orbital shaker.
  • the plate is washed 5 times as previously and drained well. 100 pL of Chemiluminescent Reagent (provided in the kit) is added to each well, including the blank wells. The plate is incubated at r.t. for 5 min. on an orbital shaker before the luminescence of each microwell is read on a plate luminometer. The % inhibition is calculated relative to the DMSO control wells after a background level of the “no lysate control” is subtracted from all the values. IC50 determination is performed by fitting the curve of inhibitor percent inhibition versus the log of the inhibitor concentration using the GraphPad Prism 7 software.
  • Example F Inhibition of RAS-RAF and PI3K-AKT Pathways
  • the cellular potency of compounds is determined by measuring phosphorylation of KRAS downstream effectors extracellular-signal-regulated kinase (ERK), ribosomal S6 kinase (RSK), AKT (also known as protein kinase B, PKB) and downstream substrate S6 ribosomal protein.
  • ERK extracellular-signal-regulated kinase
  • RSK ribosomal S6 kinase
  • AKT also known as protein kinase B, PKB
  • ERK extracellular-signal-regulated kinase
  • RSK ribosomal S6 kinase
  • AKT phosphorylated extracellular-signal-regulated kinase
  • S6 kinase ribosomal S6 kinase
  • Table 2 phosphorylated extracellular-signal-regulated kinase
  • RSK ribosomal S6 kinase
  • AKT S6 ribosomal protein
  • Ten or twenty pg of total protein lysates is subjected to SDS-PAGE and immunoblot analysis using following antibodies: phospho-ERK1/2-Thr202/Tyr204 (#9101 L), total-ERK1/2 (#9102L), phosphor-AKT-Ser473 (#4060L), phospho-p90RSK-Ser380 (#11989S) and phospho-S6 ribosomal protein-Ser235/Ser236 (#2211S) are from Cell Signaling Technologies (Danvers, MA).
  • MIA-PaCa-2 (KRAS G12C), H358 (KRAS G12C), HPAF-II (KRAS G12D), AGS (KRAS G12D ), SW480 (KRAS G12V) or YAPC(KRAS G12V) human cancer cells are obtained from the American Type Culture Collection and maintained in RPMI media supplemented with 10% FBS.
  • 5 x 106 cells are inoculated subcutaneously into the right hind flank of 6- to 8-week-old BALB/c nude mice (Charles River Laboratories, Wilmington, MA, USA). When tumor volumes are approximately 150-250 mm3, mice are randomized by tumor volume and compounds are orally administered.
  • Tumor volume is calculated using the formula (L x W2)/2, where L and W refer to the length and width dimensions, respectively.
  • Tumor growth inhibition is calculated using the formula (1 - (VT/VC)) x 100, where VT is the tumor volume of the treatment group on the last day of treatment, and VC is the tumor volume of the control group on the last day of treatment.
  • Two-way analysis of variance with Dunnett’s multiple comparisons test is used to determine statistical differences between treatment groups (GraphPad Prism). Mice are housed at ID- 12 animals per cage, and are provided enrichment and exposed to 12-h light/dark cycles. Mice whose tumor volumes exceeded limits (10% of body weight) are humanely euthanized by CO2 inhalation.
  • Caco-2 cells are grown at 37 °C in an atmosphere of 5% CO2 in DM EM growth medium supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) nonessential amino acids, penicillin (100 U/mL), and streptomycin (100 pg/mL). Confluent cell monolayers are subcultured every 7 days or 4 days for Caco-2 by treatment with 0.05% trypsin containing 1 pM EDTA. Caco-2 cells are seeded in 96-well Transwell plates. The seeding density for Caco-2 cells is 14,000 cells/well. DMEM growth medium is replaced every other day after seeding. Cell monolayers are used for transport assays between 22 and 25 days for Caco-2 cells.
  • HBSS HBSS
  • the TEER is measured by using a REMS Autosampler to ensure the integrity of the cell monolayers. Caco-2 cell monolayers with TEER values > 300 -cm 2 are used for transport experiments.
  • solution of test compound (50 pM) in HBSS is added to the donor compartment (apical side), while HBSS solution with 4% BSA is added to the receiver compartment (basolateral side).
  • the apical volume was 0.075 mL
  • the basolateral volume is 0.25 mL.
  • the incubation period is 120 min. at 37 °C in an atmosphere of 5% CO2.
  • samples from the donor and receiver sides are removed and an equal volume of MeCN is added for protein precipitation.
  • the supernatants are collected after centrifugation (3000 rpm, Allegra X-14R Centrifuge from Beckman Coulter, Indianapolis, IN) for LCMS analysis.
  • the permeability value is determined according to the equation:
  • Pa PP (cm/s) (F * VD)/(SA * MD), where the flux rate (F, mass/time) is calculated from the slope of cumulative amounts of compound of interest on the receiver side, SA is the surface area of the cell membrane, VD is the donor volume, and MD is the initial amount of the solution in the donor chamber.
  • the whole blood stability of the exemplified compounds is determined by LC-MS/MS.
  • the 96- Well Flexi-TierTM Block (Analytical Sales & Services, Inc, Flanders, NJ) is used for the incubation plate containing 1.0 mL glass vials with 0.5 mL of blood per vial (pooled gender, human whole blood sourced from BIOIVT, Hicksville, NY or similar). Blood is prewarmed in water bath to 37 °C for 30 min.
  • 96-deep well analysis plate is prepared with the addition of 100 pL ultrapure water/well. 50 pL chilled ultrapure water/well is added to 96- deep well sample collection plate and covered with a sealing mat.
  • DM SO 0.5 mM compound working solution
  • Blood is allowed to sit in the water for 2 min. and then 400 pL stop solution/well is added (MeCN containing an internal standard).
  • the incubation plate is placed in the Incu-Shaker CO2 Mini incubator (Benchmark Scientific, Sayreville, NJ) at 37 °C with shaking at 150 rpm. At 1, 2 and 4-hr, the blood samples are mixed thoroughly by pipetting and 50 pL is transferred into the corresponding wells of the sample collection plate. Blood is allowed to sit in the water for 2 min.
  • test compounds are incubated with human liver microsomes at 37 °C.
  • the incubation mixture contains test compounds (1 pM), NADPH (2 mM), and human liver microsomes (0.5 mg protein /mL) in 100 mM phosphate buffer (pH 7.4).
  • the mixture is pre-incubated for 2 min at 37 °C before the addition of NADPH. Reactions are commenced upon the addition of NADPH and quenched with ice- cold methanol at 0, 10, 20, and 30 min. Terminated incubation mixtures are analyzed using LC-MS/MS system.
  • the analytical system consisted of a Shimadzu LC-30AD binary pump system and SIL-30AC autosampler (Shimadzu Scientific Instruments, Columbia, MD) coupled with a Sciex Triple Quad 6500+ mass spectrometer from Applied Biosystems (Foster City, CA). Chromatographic separation of test compounds and internal standard is achieved using a Hypersil Gold C18 column (50 x 2.1 mm, 5 pM, 175 A) from ThermoFisher Scientific (Waltham, MA). Mobile phase A consists of 0.1% formic acid in water, and mobile phase B consists of 0.1% formic acid in MeCN. The total LC-MS/MS runtime can be 2.75 min. with a flow rate of 0.75 mL/min. Peak area integrations and peak area ratio calculations are performed using Analyst software (version 1.6.3) from Applied Biosystems.
  • CLmt in vitro
  • the CLj n t,/nvffro values are scaled to the in vivo values for human by using physiologically based scaling factors, hepatic microsomal protein concentrations (45 mg protein/g liver), and liver weights (21 g/kg body weight).
  • CLint CLint, invitro* (mg protein/g liver weight)x(g liver weight/kg body weight) is used.
  • the hepatic extraction ratio is calculated as CLH divided by Q.
  • test compounds are administered to male Sprague Dawley rats or male and female Cynomolgus monkeys intravenously or via oral gavage.
  • IV intravenous
  • test compounds are dosed at 0.5 to 1 mg/kg using a formulation of 10% dimethylacetamide (DMAC) in acidified saline via IV bolus for rat and 5 min or 10 min IV infusion for monkey.
  • DMAC dimethylacetamide
  • PO oral
  • test compounds are dosed at 1.0 to 3.0 mg/kg using 5% DMAC in 0.5% methylcellulose in citrate buffer (pH 2.5). Blood samples are collected at predose and various time points up to 24 h postdose.
  • All blood samples are collected using EDTA as the anticoagulant and centrifuged to obtain plasma samples.
  • the plasma concentrations of test compounds are determined by LC-MS methods.
  • the measured plasma concentrations are used to calculate PK parameters by standard noncompartmental methods using Phoenix® WinNonlin software program (version 8.0, Pharsight Corporation).
  • This assay is designed to characterize an increase in CYP inhibition as a test compounds is metabolized over time.
  • Potential mechanisms for this include the formation of a tight-binding, quasi-irreversible inhibitory metabolite complex or the inactivation of P450 enzymes by covalent adduct formation of metabolites. While this experiment employs a 10- fold dilution to diminish metabolite concentrations and therefore effects of reversible inhibition, it is possible (but not common) that a metabolite that is an extremely potent CYP inhibitor could result in a positive result.
  • the results are from a cocktail of CYP specific probe substrates at 4 times their Km concentrations for CYP2C9, 2C19, 2D6 and 3A4 (midazolam) using human liver microsomes (HLM).
  • HLMs can be pre-incubated with test compounds at a concentration 10 pM for 30 min in the presence (+N) or absence ( -N) of a NADPH regenerating system, diluted 10- fold, and incubated for 8 min in the presence of the substrate cocktail with the addition of a fresh aliquot of NADPH regenerating system.
  • a calibration curve of metabolite standards can be used to quantitatively measure the enzyme activity using LC-MS/MS.
  • the analytical system consists of a Shimadzu LC-30AD binary pump system and SIL-30AC autosampler (Shimadzu Scientific Instruments, Columbia, MD) coupled with a Sciex Triple Quad 6500+ mass spectrometer from Applied Biosystems (Foster City, CA). Chromatographic separation of test compounds and internal standard can be achieved using an ACQUITY UPLC BEH 130A, 2.1 x 50 mm, 1.7 pm HPLC column (Waters Corp, Milford, MA). Mobile phase A consists of 0.1% formic acid in water, and mobile phase B consists of 0.1% formic acid in MeCN. The total LC-MS/MS runtime will be 2.50 min. with a flow rate of 0.9 mL/min. Peak area integrations and peak area ratio calculations are performed using Analyst software (version 1.6.3) from Applied Biosystems.
  • the percentage of control CYP2C9, CYP2C19, CYP2D6, and CYP3A4 activity remaining following preincubation of the compounds with NADPH is corrected for the corresponding control vehicle activity and then calculated based on 0 min. as 100%.
  • a linear regression plot of the natural log of % activity remaining versus time for each isozyme is used to calculate the slope.
  • the -slope is equal to the rate of enzyme loss, or the K O bs.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de formule I, des méthodes d'utilisation des composés servant à inhiber l'activité de KRAS et des compositions pharmaceutiques contenant de tels composés. Les composés sont utiles dans le traitement, la prévention ou l'atténuation de maladies ou de troubles associés à l'activité de KRAS tels que le cancer.
PCT/US2023/069872 2022-07-11 2023-07-10 Composés tricycliques fusionnés en tant qu'inhibiteurs de mutants kras g12v WO2024015731A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263368124P 2022-07-11 2022-07-11
US63/368,124 2022-07-11
US202363496840P 2023-04-18 2023-04-18
US63/496,840 2023-04-18

Publications (1)

Publication Number Publication Date
WO2024015731A1 true WO2024015731A1 (fr) 2024-01-18

Family

ID=87556128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/069872 WO2024015731A1 (fr) 2022-07-11 2023-07-10 Composés tricycliques fusionnés en tant qu'inhibiteurs de mutants kras g12v

Country Status (2)

Country Link
US (1) US20240101557A1 (fr)
WO (1) WO2024015731A1 (fr)

Citations (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
WO2000009495A1 (fr) 1998-08-11 2000-02-24 Novartis Ag Derives d'isoquinoline possedant une activite d'inhibition de l'angiogenese
WO2000053595A1 (fr) 1999-03-06 2000-09-14 Astrazeneca Ab Composes pyrimidine
WO2001014402A1 (fr) 1999-08-19 2001-03-01 Isis Pharmaceuticals, Inc. Modulation anti-sens de l'expression de l'adhesion focale
WO2001064655A1 (fr) 2000-03-01 2001-09-07 Astrazeneca Ab 2, 4-di(hetero-)arylamino (-oxy) pyrimidines substitues en 5, utilises comme agents antineoplasiques
WO2002000196A2 (fr) 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Procede de broyage par voie humide
WO2003024967A2 (fr) 2001-09-19 2003-03-27 Aventis Pharma S.A. Composes chimiques
WO2003037347A1 (fr) 2001-10-30 2003-05-08 Novartis Ag Derives de staurosporine inhibiteurs de l'activite tyrosine kinase du recepteur flt3
WO2003042402A2 (fr) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents modulant l'activite de cellules immunes et procedes d'utilisation associes
WO2003062236A1 (fr) 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
WO2003099771A2 (fr) 2002-05-29 2003-12-04 Novartis Ag Derives de diaryle-uree utilises pour le traitement des maladies dependant des proteines kinases
WO2004005281A1 (fr) 2002-07-05 2004-01-15 Novartis Ag Inhibiteurs de tyrosine kinases
WO2004046120A2 (fr) 2002-11-15 2004-06-03 Vertex Pharmaceuticals Incorporated Diaminotriazoles convenant comme inhibiteurs de proteine kinases
WO2004056786A2 (fr) 2002-12-20 2004-07-08 Pfizer Products Inc. Composes pour traiter le developpement anormal de cellules
WO2004080980A1 (fr) 2003-03-14 2004-09-23 Novartis Ag 2,4-di(phenylamino)pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire
WO2005028444A1 (fr) 2003-09-24 2005-03-31 Novartis Ag Derives d'isoquinilone 1,4-disubstitues en tant qu'inhibiteurs de raf-kinase utiles pour le traitement de maladies proliferantes
WO2006056399A2 (fr) 2004-11-24 2006-06-01 Novartis Ag Combinaisons d'inhibiteurs de kinase jak
WO2008156712A1 (fr) 2007-06-18 2008-12-24 N. V. Organon Anticorps dirigés contre le récepteur humain de mort programmée pd-1
US7488802B2 (en) 2002-12-23 2009-02-10 Wyeth Antibodies against PD-1
WO2009085185A1 (fr) 2007-12-19 2009-07-09 Amgen Inc. Composés condensés de pyridine, de pyrimidine et de triazine en tant qu'inhibiteurs du cycle cellulaire
WO2010036959A2 (fr) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Anticorps anti-pd-1, pd-l1, et pd-l2 humains et leurs utilisations
US7745437B2 (en) 2004-06-10 2010-06-29 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2010075074A1 (fr) 2008-12-22 2010-07-01 Eli Lilly And Company Inhibiteurs de protéine kinases
WO2010089411A2 (fr) 2009-02-09 2010-08-12 Universite De La Mediterranee Anticorps pd-1 et anticorps pd-l1 et leurs utilisations
US7943743B2 (en) 2005-07-01 2011-05-17 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
WO2011066342A2 (fr) 2009-11-24 2011-06-03 Amplimmune, Inc. Inhibition simultanée de pd-l1/pd-l2
WO2011082400A2 (fr) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulateurs du récepteur immunosuppresseur pd-1 et procédés d'utilisation de ceux-ci
WO2011101409A1 (fr) 2010-02-19 2011-08-25 Novartis Ag Composés de la pyrrolopyrimidine utilisés en tant qu'inhibiteurs des cdk4/6
US8008449B2 (en) 2005-05-09 2011-08-30 Medarex, Inc. Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2011159877A2 (fr) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Anticorps di-spécifiques anti-tim-3 et pd-1 pour immunothérapie dans des états pathologiques immuns chroniques
WO2011161699A2 (fr) 2010-06-25 2011-12-29 Aurigene Discovery Technologies Limited Composés modulateurs de l'immunosuppression
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2012061156A1 (fr) 2010-10-25 2012-05-10 Tavares Francis X Inhibiteurs de cdk
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
WO2012129344A1 (fr) 2011-03-23 2012-09-27 Amgen Inc. Doubles inhibiteurs tricycliques fusionnés de cdk 4/6 et de flt3
US20170145025A1 (en) 2015-11-19 2017-05-25 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170174679A1 (en) 2015-12-22 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170174671A1 (en) 2015-12-17 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170320875A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170362253A1 (en) 2016-06-20 2017-12-21 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180177870A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Immunomodulator compounds and methods of use
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180179197A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20190127467A1 (en) 2015-07-30 2019-05-02 Macrogenics, Inc. PD-1-Binding Molecules and Methods of Use Thereof
US20190144439A1 (en) 2015-10-19 2019-05-16 Incyte Corporation Heterocyclic compounds as immunomodulators
US20190300524A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Heterocyclic compounds as immunomodulators
US20190345170A1 (en) 2018-05-11 2019-11-14 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2021211864A1 (fr) * 2020-04-16 2021-10-21 Incyte Corporation Inhibiteurs de kras tricycliques fusionnés
WO2023064857A1 (fr) * 2021-10-14 2023-04-20 Incyte Corporation Composés de quinoléine utiles en tant qu'inhibiteurs de kras
WO2023091746A1 (fr) * 2021-11-22 2023-05-25 Incyte Corporation Polythérapie comprenant un inhibiteur de fgfr et un inhibiteur de kras

Patent Citations (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
WO2000009495A1 (fr) 1998-08-11 2000-02-24 Novartis Ag Derives d'isoquinoline possedant une activite d'inhibition de l'angiogenese
WO2000053595A1 (fr) 1999-03-06 2000-09-14 Astrazeneca Ab Composes pyrimidine
WO2001014402A1 (fr) 1999-08-19 2001-03-01 Isis Pharmaceuticals, Inc. Modulation anti-sens de l'expression de l'adhesion focale
WO2001064655A1 (fr) 2000-03-01 2001-09-07 Astrazeneca Ab 2, 4-di(hetero-)arylamino (-oxy) pyrimidines substitues en 5, utilises comme agents antineoplasiques
WO2002000196A2 (fr) 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Procede de broyage par voie humide
WO2003024967A2 (fr) 2001-09-19 2003-03-27 Aventis Pharma S.A. Composes chimiques
WO2003037347A1 (fr) 2001-10-30 2003-05-08 Novartis Ag Derives de staurosporine inhibiteurs de l'activite tyrosine kinase du recepteur flt3
WO2003042402A2 (fr) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents modulant l'activite de cellules immunes et procedes d'utilisation associes
WO2003062236A1 (fr) 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
WO2003099771A2 (fr) 2002-05-29 2003-12-04 Novartis Ag Derives de diaryle-uree utilises pour le traitement des maladies dependant des proteines kinases
WO2004005281A1 (fr) 2002-07-05 2004-01-15 Novartis Ag Inhibiteurs de tyrosine kinases
WO2004046120A2 (fr) 2002-11-15 2004-06-03 Vertex Pharmaceuticals Incorporated Diaminotriazoles convenant comme inhibiteurs de proteine kinases
WO2004056786A2 (fr) 2002-12-20 2004-07-08 Pfizer Products Inc. Composes pour traiter le developpement anormal de cellules
US7488802B2 (en) 2002-12-23 2009-02-10 Wyeth Antibodies against PD-1
WO2004080980A1 (fr) 2003-03-14 2004-09-23 Novartis Ag 2,4-di(phenylamino)pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire
WO2005028444A1 (fr) 2003-09-24 2005-03-31 Novartis Ag Derives d'isoquinilone 1,4-disubstitues en tant qu'inhibiteurs de raf-kinase utiles pour le traitement de maladies proliferantes
US7745437B2 (en) 2004-06-10 2010-06-29 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2006056399A2 (fr) 2004-11-24 2006-06-01 Novartis Ag Combinaisons d'inhibiteurs de kinase jak
US8008449B2 (en) 2005-05-09 2011-08-30 Medarex, Inc. Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US7943743B2 (en) 2005-07-01 2011-05-17 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
WO2008156712A1 (fr) 2007-06-18 2008-12-24 N. V. Organon Anticorps dirigés contre le récepteur humain de mort programmée pd-1
WO2009085185A1 (fr) 2007-12-19 2009-07-09 Amgen Inc. Composés condensés de pyridine, de pyrimidine et de triazine en tant qu'inhibiteurs du cycle cellulaire
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010036959A2 (fr) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Anticorps anti-pd-1, pd-l1, et pd-l2 humains et leurs utilisations
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
WO2010075074A1 (fr) 2008-12-22 2010-07-01 Eli Lilly And Company Inhibiteurs de protéine kinases
WO2010089411A2 (fr) 2009-02-09 2010-08-12 Universite De La Mediterranee Anticorps pd-1 et anticorps pd-l1 et leurs utilisations
WO2011066342A2 (fr) 2009-11-24 2011-06-03 Amplimmune, Inc. Inhibition simultanée de pd-l1/pd-l2
WO2011082400A2 (fr) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulateurs du récepteur immunosuppresseur pd-1 et procédés d'utilisation de ceux-ci
WO2011101409A1 (fr) 2010-02-19 2011-08-25 Novartis Ag Composés de la pyrrolopyrimidine utilisés en tant qu'inhibiteurs des cdk4/6
WO2011159877A2 (fr) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Anticorps di-spécifiques anti-tim-3 et pd-1 pour immunothérapie dans des états pathologiques immuns chroniques
WO2011161699A2 (fr) 2010-06-25 2011-12-29 Aurigene Discovery Technologies Limited Composés modulateurs de l'immunosuppression
WO2012061156A1 (fr) 2010-10-25 2012-05-10 Tavares Francis X Inhibiteurs de cdk
WO2012129344A1 (fr) 2011-03-23 2012-09-27 Amgen Inc. Doubles inhibiteurs tricycliques fusionnés de cdk 4/6 et de flt3
US20190127467A1 (en) 2015-07-30 2019-05-02 Macrogenics, Inc. PD-1-Binding Molecules and Methods of Use Thereof
US20190144439A1 (en) 2015-10-19 2019-05-16 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170145025A1 (en) 2015-11-19 2017-05-25 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180273519A1 (en) 2015-12-17 2018-09-27 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170174671A1 (en) 2015-12-17 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170174679A1 (en) 2015-12-22 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170320875A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US20190071439A1 (en) 2016-05-06 2019-03-07 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
US20190040082A1 (en) 2016-06-20 2019-02-07 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170362253A1 (en) 2016-06-20 2017-12-21 Incyte Corporation Heterocyclic compounds as immunomodulators
US20190062345A1 (en) 2016-06-20 2019-02-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20190202824A1 (en) 2016-12-22 2019-07-04 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180179197A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180177870A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Immunomodulator compounds and methods of use
US20190225601A1 (en) 2016-12-22 2019-07-25 Incyte Corporation Heterocyclic compounds as immunomodulators
US20190300524A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Heterocyclic compounds as immunomodulators
US20190345170A1 (en) 2018-05-11 2019-11-14 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2021211864A1 (fr) * 2020-04-16 2021-10-21 Incyte Corporation Inhibiteurs de kras tricycliques fusionnés
WO2023064857A1 (fr) * 2021-10-14 2023-04-20 Incyte Corporation Composés de quinoléine utiles en tant qu'inhibiteurs de kras
WO2023091746A1 (fr) * 2021-11-22 2023-05-25 Incyte Corporation Polythérapie comprenant un inhibiteur de fgfr et un inhibiteur de kras

Non-Patent Citations (33)

* Cited by examiner, † Cited by third party
Title
"Comprehensive Heterocyclic Chemistry", 1984, PERGAMON PRESS
"Comprehensive Organic Functional Group Transformations", 1996, MEDICAL ECONOMICS COMPANY
"Comprehensive Organic Synthesis", 1991, PERGAMON PRESS
"Journal of Heterocyclic Chemistry", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 1-107, pages 1964 - 2012
"Pharmaceutical Preformulation and Formulation", 2009, THE PHARMACEUTICAL PRESS AND THE AMERICAN PHARMACEUTICAL ASSOCIATION
"Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1418
A. KEREKES, J. MED. CHEM., vol. 54, 2011, pages 201 - 210
ALAN F. THOMAS: "Deuterium Labeling in Organic Chemistry", 1971, APPLETON-CENTURY-CROFTS
BERGE ET AL., J. PHARM. SCI., vol. 66, no. 1, 1977, pages 1 - 19
COX, A.D. ET AL., NAT REV DRUG DISCOV, vol. 13, 2014, pages 828 - 51
COX, A.D. ET AL., NAT. REV. DRUG DISCOV., vol. 13, 2014, pages 828 - 51
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2023, ARJONA ET AL.: "Combination therapy comprising a fibroblast growth factor receptor (FGFR) inhibitor and a Kras protein inhibitor for treating cancer", XP093076647, Database accession no. 2023:1064483 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2023, YE ET AL.: "Quinoline compounds as inhibitors of KRAS", XP093076644, Database accession no. 2023:801315 *
FERNANDEZ-MEDARDE, A. ET AL., GENES & CANCER, 2011, pages 344 - 358
JENS ATZRODTVOLKER DERDAUTHORSTEN FEYJOCHEN ZIMMERMANN: "March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 2007, GOWER PUBLISHING COMPANY, article "The Renaissance of H/D Exchange", pages: 7744 - 7765
JENS ATZRODTVOLKER DERDAUTHORSTEN FEYJOCHEN ZIMMERMANN: "The Renaissance of H/D Exchange", ANGEW. CHEM. INT. ED., 2007, pages 7744 - 7765, XP055192405, DOI: 10.1002/anie.200700039
K. BLOM: "Two-Pump At Column Dilution Configuration for Preparative LC-MS", J. COMBI. CHEM., vol. 4, 2002, pages 295
K. BLOMB. GLASSR. SPARKSA. COMBS: "Preparative LCMS Purification: Improved Compound Specific Method Optimization", J. COMB. CHEM., vol. 6, 2004, pages 874 - 883
K. BLOMB. GLASSR. SPARKSA. COMBS: "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", J. COMBI. CHEM., vol. 6, 2004, pages 874 - 883
K. BLOMR. SPARKSJ. DOUGHTYG. EVERLOFT. HAQUEA. COMBS: "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", J. COMBI. CHEM., vol. 5, 2003, pages 670
KARL F. BLOMBRIAN GLASSRICHARD SPARKSANDREW P: "Preparative LCMS Purification: Improved Compound Specific Method Optimization", COMBS J. COMBI. CHEM., vol. 6, no. 6, 2004, pages 874 - 883
KNICKELBEIN, GENES & CANCER, 2015, pages 4 - 12
KNOWLEDGE UPDATES KU, vol. 1-48, 2010, pages 2001 - 2010
KOCIENSKI, PROTECTING GROUPS, 2007
LAROCK: "Comprehensive Organic Transformations: A Guide to Functional Group Preparations", 1999, WILEY
MCDONALD, R. ET AL., CELL, vol. 170, no. 1, 2017, pages 577 - 592
PETURSSION ET AL.: "Protecting Groups in Carbohydrate Chemistry", J. CHEM. EDUC., vol. 74, no. 11, 1997, pages 1297
R. XU, J. LABEL COMPD. RADIOPHARM, vol. 58, 2015, pages 308 - 312
R. XU, J. LABEL COMPD. RADIOPHARM., vol. 58, 2015, pages 308 - 312
ROBERTSON: "Protecting Group Chemistry", 2000, OXFORD UNIVERSITY PRESS
SAKAMOTO ET AL., BBRC, vol. 484, no. 3, 2017, pages 605 - 611
WUTS ET AL.: "Protective Groups in Organic Synthesis", 2006, WILEY

Also Published As

Publication number Publication date
US20240101557A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
US11530218B2 (en) Spiro compounds as inhibitors of KRAS
US11739102B2 (en) Fused pyrimidine compounds as KRAS inhibitors
US11607416B2 (en) Bicyclic heterocycles as FGFR inhibitors
US11767320B2 (en) Bicyclic dione compounds as inhibitors of KRAS
WO2021007269A1 (fr) Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
CA3163875A1 (fr) Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2022047093A1 (fr) Composés d'imidazole vinylique en tant qu'inhibiteurs de kras
AU2022306671A1 (en) Tricyclic compounds as inhibitors of kras
WO2023034290A1 (fr) Composés de naphtyridine en tant qu'inhibiteurs de kras
US11939328B2 (en) Quinoline compounds as inhibitors of KRAS
CA3220274A1 (fr) Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
EP4370515A1 (fr) Composés tricycliques utiles en tant qu'inhibiteurs de kras
US20220389033A1 (en) Hetero-bicyclic inhibitors of kras
WO2024015731A1 (fr) Composés tricycliques fusionnés en tant qu'inhibiteurs de mutants kras g12v
US11999752B2 (en) Vinyl imidazole compounds as inhibitors of KRAS
TW202412759A (zh) 做為kras g12v突變體抑制劑之稠合三環化合物
US20230151005A1 (en) Hetero-tricyclic compounds as inhibitors of kras
WO2023056421A1 (fr) Inhibiteurs de kras tels que la pyrazoloquinoline

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23751219

Country of ref document: EP

Kind code of ref document: A1